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‘We choose to go to the Moon...We choose to go to the Moon in this decade 
and do the other things, not because they are easy, but because they are hard.’ 
 
 
—John F. Kennedy  
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Background and aims 
In recent decades, prognosis amongst acute coronary syndrome (ACS) 
patients has improved. However, adherence to secondary prevention therapies 
recommended by guidelines appears insufficient, thereby affecting ACS 
patients’ survival, particularly in relation to statins. Furthermore, the 
prognostic benefit of widely used -blockers following ACS, especially 
amongst low-risk patients, has been disputed. In addition, despite 
contraindications, ACS patients continue relying upon nonsteroidal 
antiinflammatory drugs (NSAIDs), which may prove even fatal. Increasingly, 
guidelines have been unable to establish recommendations for the safe use of 
red blood cell (RBC) transfusions in an ACS setting. Thus, this study aimed to 
explore the adherence rates to statins and -blockers as well as the utilisation 
rate of prescription NSAIDs and their impact on long-term survival amongst 
ACS patients. Additionally, we sought to determine the effect of RBC 
transfusion therapy on ACS patients’ long-term morbidity and mortality. 
 
Material and methods 
From 5294 consecutive patients undergoing a coronary angiography (CAG) 
between 2006 and 2008 in the Genetic Predisposition for Coronary Artery 
Disease Study (COROGENE), 2090 patients were initially diagnosed with 
ACS, upon which studies I through IV in this study are based. To assess the 
utilisation of prescription medications in studies I, III and IV, we obtained 
data from the Finnish Prescription Register of the Social Insurance Institute 
(SII) and gathered mortality figures with causes of death from Statistics 
Finland. In studies II through IV, the Care Register for Health Care (HILMO) 
from the Finnish Institute for Health and Welfare was used to assess the 
recurrence of hospitalisations for different reasons. In study II, we merged 
data on transfusions and haemoglobin (Hb) values from a comprehensive 
hospital transfusion registry of the Hospital District of Helsinki and Uusimaa 
(HUS). The primary endpoint in studies I through III was all-cause mortality, 
whilst in study IV we assessed composite endpoint of recurrent myocardial 
infarction (MI) and all-cause mortality. Median follow-up was 23 months in 
study I, 8.6 years in studies II and III and 8.7 years in study IV.  
 
Main results 
In study I when comparing regular statin users (61.7%, n = 1200/1945) to 
irregular users (33.5%, n = 651/1945) and nonusers (4.8%, n = 94/1945), we 
observed a stepwise increase in mortality (4.9%, 9.4% and 14.9%, respectively, 
p < 0.001). The relative risk of mortality was almost threefold higher for 
nonusers compared to regular users in a multivariable Cox proportional 
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hazards model [hazard ratio (HR) 2.70, (95% confidence interval (CI) 1.49–
4.90), p = 0.001]. 
In study II, we compared RBC transfused patients (4.4%, n = 85/1937) to 
nontransfused patients (66.0%, n = 1278/1937). RBC transfused patients 
exhibited a worse long-term prognosis considering both absolute mortality 
(58.8% vs. 20.3%, p < 0.001) and an adjusted multivariable Cox regression 
model [HR 1.91 (95%CI 1.39–2.63), p < 0.001]. After matching 65 patients 
from each group in a 1:1 fashion based on their propensity score, results 
remained rather consistent [HR 2.70 (95%CI 1.48–4.95), p = 0.001]. The 
inverse probability treatment weighted (IPTW) model further confirmed our 
results [HR 2.07 (95%CI 1.38–3.11), p < 0.001]. 
In study III, we assessed adherence to -blockers separately for each yearly 
period of follow-up and examined adherence as a time-dependent variable in 
the Cox proportional hazards model. In a multivariable model adjusted for the 
concomitant use of other secondary prevention medications, nonadherence to 
-blockers associated with an increased risk of mortality for both overall 
survival (OS) [HR 1.84 (95%CI 1.51–2.24), p < 0.001] and on one-year 
landmark survival (1YLS) [HR 1.74 (95%CI 1.41–2.14), p < 0.001]. The effect 
on all-cause mortality was also seen within the low-risk patient subgroup [HR 
1.60 (95%CI 1.16–2.21), p = 0.004]. 
As many as 54.3% (n = 1042/1919) of patients filled at least one NSAID 
prescription during the entire follow-up period in study IV. Yearly use, defined 
as ≥1 prescription filled per year, decreased slightly from a peak of 22.4% 
during the second year to 14.5% during the eighth year of follow-up. Current 
use of NSAID (4.6%, n = 88/1919), defined by the number of days’ supply for 
the most recent prescription filled lasting up to at least 30 days before the 
outcome event, was associated with an increased risk of a composite outcome 
in a mutltivariable adjusted logistic regression model [OR 1.75 (95%CI 1.10–
2.78), p = 0.019]. However, we observed no difference in the absolute rates of 
the composite outcome when comparing current users with nonusers (53.4% 
vs. 48.5%, p = 0.368). The finding was repeated in the multivariable analyses 




The risk of mortality appears to incrementaly rise with the level of 
nonadherence to statins amongst ACS patients. Nonadherence to -blockers 
also associated with an increased risk of death, even beyond the first year 
following an ACS event. Furthermore, low-risk patients also appear to benefit 
from continuous -blocker therapy. Alarmingly, despite contraindications 
many ACS patients continue using prescribed NSAIDs and their use associated 
with an increased risk of recurrent MI and death. Finally, RBC transfusion 
associated with a poorer prognosis amongst ACS patients, even during long-




Much has been achieved in recent decades towards improving both primary 
prevention of and treatment for coronary artery disease (CAD) in general. Yet, 
whilst slightly declining, ischemic heart disease remains the leading cause of 
death in Finland, Europe and globally.1-3 The incidence of a first myocardial 
infarction (MI) has decreased due to the evolution of effective primary 
prevention and an increased knowledge of the disease and its risk factors. 
Diagnostics, treatment algoritms, medications as well as revascularisation 
techniques used to treat acute coronary syndrome (ACS) patients have also 
evolved substantially in the last 20 years. These measures have improved both 
the short- and long-term outcomes for coronary patients. Moreover, with 
advanced treatment options, MI amongst increasingly fragile and older 
patients can also now be treated.4-8  
However, effective antithrombotic medications carry the risk of bleeding. 
In recent years, increasing attention has been paid to bleeding complications 
and their effect on ACS patient survival.9,10 Red blood cell (RBC) transfusion 
has been widely used to correct anaemic and bleeding patients’ haemoglobin 
(Hb) levels to ensure oxydation of a vulnerable myocardium during ACS.11 
Recenlty, however, in addition to adverse reactions, long-term morbidity and 
mortality have been linked to RBC transfusion treatment. Aside from ACS 
patients, guidelines recommend a conservative approach to RBC transfusion 
in practically every setting. Amongst ACS patients, however, studies remain 
contradictory and, therefore, conclusive recommendations are lacking.12-14 
 There is room for a magnitude of improvements to optimal secondary 
prevention, particularly related to adherence to evidence-based medical 
therapies. Recent studies show that 5% to 20% of MI patients do not use the 
medications prescribed to them.15-17 Furthermore, as many as 20% to 50% of 
patients use medications irregularly or discontinue them within the first years 
of follow-up. During follow-up, nonadherence increases further. This pattern 
is seen within all secondary preventive medications, but particularly with 
statins.18-20 
In addition, given the widespread use of modern revascularisation 
therapies, the role of well-known and commonly used -adrenergic receptor 
blockers (simply, -blockers) in the treatment of ACS patients, particularly 
amongst those with a low residual risk, has been questioned.21 Only a few 
randomised controlled trials (RCTs) have been conducted in the reperfusion 
era, with contradictory findings.22,23 Observational studies have provided 
evidence both for and against their use amongst patients with preserved left-
ventricular (LV) function. Yet, some studies propose that, amongst such 
patients, 1 to 3 years of therapy would be sufficient, whereas other studies 
recommend permanent -blocker treatment for all ACS patients.24-34 Thus, 
consensus has yet to be reached on this topic as well. 
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Nonsteroidal antiinflammatory drugs (NSAIDs) represent the most 
broadly used medications to ease pain, fever and inflammation.35 Amongst 
coronary patients, comorbidities often requiring pain relief, such as 
rheumatoid arthritis or arthrosis, remain fairly common. Following the advent 
of cyclooxygenase (COX)-2 selective coxibs at the beginning of the twenty-first 
century, the adverse cardiac effects associated with all NSAIDs were 
identified.36-41 These findings led to restrictions and recommendations against 
their use amongst cardiac patients.42,43 Yet, alarmingly many ACS patients 
continue to use NSAIDs.35,43-48 To what extent and with what sort of results 
remain unclear, at least in Finland. 
Thus, this study aimed to investigate these issues contributing to ACS 
patients’ long-term survival in the modern reperfusion era. We sought to 
examine the utilisation of prognostic secondary prevention medications, 
namely, statins and -blockers, as well as potentially life-threatening NSAIDs. 
Furthermore, we investigated their effect on ACS patients’ morbidity and 
mortality. In addition, we sought to determine the prevalence and impact of 
RBC transfusion treatment on long-term outcomes. 
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2 REVIEW OF THE LITERATURE 
2.1 ACUTE CORONARY SYNDROME  
Typically, a patient presenting with acute chest pain or shortness of breath 
initiates a diagnostic and treatment cascade for suspected ACS. As the name 
of the syndrome depicts, the setting has evolved rapidly and the propable 
culprit of the incident lies within the coronary arteries. Described in more 
detail below, ACS falls into two main categories based on clinical findings as 
well as pathophysiological and prognostic features. These are: 
 
1) ST-segment elevation myocardial infarction (STEMI) and 
2) Non-ST-segment elevation acute coronary syndrome (NSTE-ACS), 
which further falls into the final diagnoses of: 
a. Non-ST-segment elevation myocardial infarction (NSTEMI) and 
b. Unstable angina pectoris (UAP). 
2.1.1 EPIDEMIOLOGY 
Despite significant achievements in both preventing and treating CAD and 
ACS, ischemic heart disease remains the leading cause of death worldwide, 
accounting for 16.6% of all deaths globally, or about 9.4 million deaths 
annually.1 The World Health Organisation (WHO) estimated that in 2016 
almost 200 000 years of life were lost globally due to ischemic heart disease, 
rising from roughly 150 000 in 2000.49 Although coronary mortality in Europe 
has declined in the last three decades, around 1.8 million deaths still result 
from CAD in Europe, corresponding to 20% of all deaths.3,50 Furthermore, an 
estimated 15% to 20% of all deaths result from sudden cardiac death (SCD), a 
death that is unexpected and which typically occurs  outside of a hospital.51-54 
SCD accounts for as many as half of all cardiac deaths globally55 and is 
primarily thought to result from a fatal arrhythmia, such as ventricular 
fibrillation, often triggered by the onset of acute coronary syndrome. 
Approximately 60% to 80% of SCDs result from CAD.55,56 For instance, a 
recent Finnish study examining individuals suffering an SCD caused by 
ischemic heart disease, found that an autopsy revealed about 42% of 
previously CAD-naïve patients suffered a silent myocardial infarction.52 
Additionally, about 25% to 35% of patients suffering from acute MI, typically 
STEMI, die of SCD before reaching a medical facility.57 
In Finland, 20% of all deaths are caused by CAD; in 2018, there were 
roughly 10 000 coronary deaths.2 Furthermore, 60 000 patients are admitted 
to hospital annually because of CAD, about 15 000 patients due to an acute 
cardiac event. Whilst the incidence of ACS has steadily declined since the 
1990s, that rate has remained stable for the last 10 years in Finland.58 
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However, when examining different subtypes of ACS, in recent years, the 
relative incidence of STEMI has decreased, yet NSTEMI increased.6,8 Short-
term mortality appears greater for STEMI patients when compared to 
NSTEMI patients, although both short- and long-term mortalities, particularly 
for STEMI, continue to decline.59,60 In-hospital mortality amongst ACS 
patients in European countries varies from 4.5% to 15%, standing at 6.5% in 
Finland in 2013.50 Furthermore, 30-day short-term mortality following events 
ranged from around 2% to 8% amongst all ACS patients.7,61 In the long term, 
differences in mortality rates between STEMI and NSTEMI appear to be 
narrowing, ranging from 8% to 10% 1 year after an event.4,5,7,62-64 Amongst 
NSTE-ACS patients, long-term mortality is slightly greater than amongst 
STEMI patients, primarily explained by the older age and an increased 
comorbidity amongst NSTE-ACS patients.65,66 In a Finnish registry study, the 
1- and 3-year mortality of ACS patients surviving the first 28 days following an 
event were 12.9% and 26.5%, respectively. Accordingly, 21.6% and 32.7% of 
patients suffered a recurrent ACS within the 1- and 3-year follow-up periods, 
respectively.67 The general decline in mortality caused by ACS is primarily due 
to evolving antithrombotic therapies, particularly the more frequent and 
sophisticated reperfusion therapy—namely, primary percutaneous coronary 
intervention (PCI)—as well as a greater emphasis on secondary prevention.4,7 
Post-ACS patients are also at a greater risk for an SCD. About 5% to 10% of 
these patients die of an SCD during the first year following an ACS.68 Both an 
implantable cardioverter defibrillator (ICD) in select cases, as well as the wider 
availability and usage of automated external defibrillators (AEDs), have 
improved survival amongst ACS patients.57,68-70 
 
2.1.2 PATHOPHYSIOLOGY 
CAD is a local atherosclerotic disease of the coronary arteries with a similar 
pathology to other manifestations of atherosclerosis. Both high cholesterol 
and inflammation play key roles in the development of the disease.71-73 
Atherosclerotic plaque forms due to multiple factors, although 
hyperlipidaemia, namely, an increased consentration of low-density 
lipoprotein cholesterol (LDL-C), is essential.74-76 Other major risk factors 
affecting the development of plaque include hypertension, diabetes mellitus 
(DM), smoking, being male and genetic factors.77 
The formation of atherosclerotic plaques usually begins already during 
early adulthood. Typically, atherosclerotic plaques form along the inner 
curvatures and branching sites of the arterial tree due to shear stress caused 
by blood-flow mechanics. This mechanical stress induces changes in the 
endothelial metabolism, enabling cholesterol (especially, LDL-C) to 
accumulate along the thickened intimal layer of the artery to form fatty 
streaks.78 Simply, LDL-C particles accumulate in the arterial intima and are 
modified by oxidation and aggregation, which, in turn, stimulates the innate 
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and adaptive immune response. Given this stimulation, adhesion molecules 
are expressed in the endothelium such that monocytes accumulate at the site 
and differentiate to the macrophages. This coincides with the accumulation of 
smooth muscle cells along the intimal layer of the coronary artery, causing it 
to increasingly thicken. The recruited macrophages become foam cells acting 
as lipid deposits. Furthermore, several layers of accumulated foam cells, the 
telltale signs of lipoprotein-driven inflammation, appear microscopically as 
fatty streaks. This phase is reversible; but, if the lipids continue accumulating, 
the fatty streaks become progressive atherosclerotic lesions.75,79 The buildup 
of cholesterol along the arterial wall, in turn, induces the inflammatory 
processes, which both further promote the development of plaque into 
fibroatheroma and causes it to become more fragile.80 
As the atherosclerotic plaque grows further, it may either become 
concentric or eccentric plaque (see Figure 1).74,75 Concentric plaque is usually 
stable, with a small lipid core and thick fibrous cap at the top. Concentric 
plaque causes the arterial lumen to narrow as the fibrous cap at the top 
thickens due to continous erosion and healing in the endothelium.75,81,82 In 
turn, in eccentric plaque with a large necrotic lipidous core, the fibrous cap is 
thinner whereby positive remodelling causes it to grow outwards without 
affecting the luminal cross-section in the same manner.74 Typically, the former 
associates with stable coronary disease and causes symptoms during physical 
stress as oxygen demand in the myocardium increases. Yet, the blood flow 
remains inadequate due to stenosis of the arterial lumen. Ultimately, even a 
tiny thrombosis provoked by endothelial erosion may occlude the remainder 
of the free lumen and provoke ACS, usually NSTEMI or UAP.81,83 Typically, in 
this situation, the thrombus forming is intramural, representing a platelet-rich 
‘white’ thrombus. However, fibrin-rich ‘white’ thrombi have also been 
discovered in recent in vivo studies.84  
By contrast, eccentric plaque may become symptomatic for the first 
time when its fragile, thin fibrous cap ruptures, exposing the highly 
thrombogenic lipid core, collagen and tissue factor, triggering the platelets to 
accumulate and activate. Concomitantly, the coagulation cascade is activated, 
converting fibrinogen into fibrin. These events initiate the formation of 
thrombus. Initially, the thrombus primarily consists of aggregated platelets 
and is macroscopically characterised as a fresh ‘white’ thrombus. As the 
thrombus grows, it becomes more fibrin-rich, and stabilises as an ‘older’ red 
thrombus, such that red blood cells and inflammatory cells become entrapped 
in the fibrin network.85-87 Ultimately, the thrombus may occlude the entire 
lumen of the artery, thereby blocking the flow of blood and oxygen to the 





Figure 1 Illustration of atherosclerotic plaque types. Stable, concentric plaque with the 
subsequent superficial erosion of the endothelium and unstable, eccentric plaque 
with the complication of a deep rupture and occluding thrombosis. 
2.1.3 RISK FACTORS 
Atherosclerosis and, thus, CAD and ACS result from a number of risk 
factors.77,89 All current guidelines suggest repeated systematic assessment of a 
patient’s total cardiovascular (CV) risk to identify those at an increased risk 
due to their condition (e.g., documented CV disease, DM, renal disease, 
dyslipidaemia, smoking, hypertension and familial history), as well as 
amongst previously healthy adults over 40 years of age.90-92 Based on a total 
risk assessment, each risk factor should be treated with either lifestyle 
management or drug intervention depending on the individual risk level.90  
Dyslipidaemia with elevated cholesterol levels, especially LDL-C, is a 
crucial risk factor for CAD.76,93-96 LDL-C accumulates in the coronary arteries 
when serum LDL-C levels are elevated. Moreover, elevated LDL-C appears to 
also associate with the inflammatory processes involved in CAD.73,97 In 
addition to elevated LDL-C levels, high total cholesterol (TC) levels, low high-
density lipoprotein (HDL-C) and a high TC/HDL-C ratio associate with an 
increased risk for ACS, particularly amongst men.94,98 Triglycerides, however, 
do not appear to independently affect CAD risk on their own, but instead 
highly associate with other CV risk factors, such as obesity and DM.91,97 
Different types of treatments for dyslipidaemia have been historically 
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attempted, but only those attempting to lower the LDL-C concentration have 
demonstrably reduced the risk of MI, even with a direct proportionality to an 
absolute reduction in the LDL-C concentration.99-101 
Hypertension represents one of the most common diseases and a major 
risk factor for CAD and ACS globally.102,103 Elevated blood pressure not only 
affects the endothelial function of the arteries in favour of atherosclerotic 
plaque formation, but also puts the myocardium under an increased oxygen 
demand by increasing the heart’s workload.73,104 Both of these raise the risk of 
ACS, representing one of the reasons why hypertension should be treated 
aggressively.   
One of the major CV risk factors, although declining at least in Europe, 
remains tobacco smoking. Smoking causes oxidative stress, endothelial 
dysfunction, inflammation and carries a strong prothrombotic effect, thus 
significantly increasing the risk of acute MI.90,105,106 Smokers, particularly 
young women, amongst whom smoking is increasing, exhibit up to a three-
times higher risk for MI.90,107 
DM represents a signficiant independent risk factor for CAD and 
atherosclerosis in general. DM alone increases the risk of vascular 
complications twofold.108 Diabetes, irrespective of type (type 2 being the most 
common), affects the pathophysiology of CAD, by, for instance, inducing 
inflammation and oxidative stress through atherosclerotic plaque.109 
Although an independent risk factor itself, obesity also increases the 
incidence of DM, hypertension and dyslipidaemia.90,110 All of these combine to 
form a metabolic syndrome, which today is alarmingly common. As with many 
of others, the primary effect of obesity on CV risk is mediated through the 
promotion of inflammation.73 
In addition, genetic factors affect the course of atherosclerosis and ACS. In 
recent decades, their role has been examined in more detail.111-114 In addition 
to the individual genetic or epigenetic differences, different ethnic origins, 
ages and being male have previously associated with an elevated risk for CAD 
and MI.50  
Moreover, socioeconomic status, poverty, physical inactivity and a 
vegetable-poor diet demonstrably increase CVD risk and should likewise be 
addressed in the complete risk assessment and treatment of CAD patients.89,90 
Whilst many of the risk factors are similar for stable CAD and ACS 
pathologically, some are more specifically bound to ACS. For instance, 
habitual physical activity has been shown to reduce the baseline risk of CAD, 
although the risk of ACS and SCD is transiently elevated during vigorous 
episodes of physical activity, such as exercise. However, this risk diminishes 
through regular exercise. Other specific triggers for ACS have been previously 
identified and include sexual activity, respiratory and urinary tract infections 
as well as chemical triggers such as caffeine, alcohol, marijuana and cocaine. 
Heavy meals have also been associated with an increased risk of ACS. In 
addition, psychological triggers such as anger, depression, anxiety and work-
related stress have been associated with the onset of ACS. Furthermore, 
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population-based stressful events such as earthquakes, terror attacks and war 
have been reported as population-wide triggers for ACS.115 
2.1.4 SYMPTOMS, DIAGNOSIS AND CLASSIFICATION 
The diagnosis of ACS is based on typical symptoms, electrocardiogram 
(ECG) findings and cardiac enzymes. The diagnostic measures and primary 
treatment parallel one another in order to minimise the delay from symptom 
onset to definitive care.116,117 ACS is divided into two initial categories, STEMI 
and NSTE-ACS, which is further classified as NSTEMI and UAP based upon 
the levels of cardiac biomarkers (see Figure 2).118 Since treatment patterns 
differ based on the type of ACS, it is crucial to make a prompt initial diagnosis, 
specifically distinguishing between STEMI and NSTE-ACS based on ECG 
findings, as described below.118,119 
The most typical symptom of ACS is chest pain radiating to the neck, lower 
jaw or left arm. Less common symptoms include shortness of breath, nausea 
or vomiting, sweating, syncope, palpitations and fatigue. Atypical and mild, 
sometimes misleading symptoms are more common amongst diabetics, the 
elderly and women.116,120,121 The spectrum of symptoms presenting with ACS is 
wide, ranging from symptomless to sudden death. In NSTE-ACS, however, 
typical presentations of anginal pain are categorised as 1.) prolonged (>20 
min) pain at rest, 2.) new onset angina [class II or III of the Canadian 
Cardiovascular Society (CCS) classification],122 3.) recent destabilisation of 
previously stable angina (at least CCS III) or 4.) post-MI angina.117 
Due to changes in the electric currents caused by ischemic myocardium, 
ECG—more precisely, a persistent elevation to the ST-segment along at least 
two contiguous leads or the appearance of a new left-bundle branch block 
(LBBB)—plays a crucial role in the primary differentiation between STEMI 
and NSTE-ACS.116,123 Although an ECG might appear completely normal 
amongst NSTE-ACS patients, various ECG changes can also occur in NSTEMI 
and UAP, which include the depression of an ST segment, T-wave inversions, 
branch/fascicular blocks, a transient ST elevation or nonspecific minor 
changes.117,118 If the initial diagnosis quickly derived from the ECG findings 
points to STEMI, emergency care should be provided without further delay as 
described in the next  section. As opposed to STEMI and NSTEMI, no ischemic 
damage to the myocardium appears in UAP, which is clinically differentiated 
from the former by the absence of elevated cardiac biomarkers in the blood 
stream.117 Currently, cardiac troponins T and I (TnT and TnI), prefereably with 
a high sensitivity, are more often used, serving as the most significant 
biomarkers in diagnosing myocardial ischemia.124,125 As cardiac biomarkers in 
MI, troponins increase rapidly after the onset of symptoms, usually within the 
first hour, and typically remain elevated for several days. For an NSTEMI 
diagnosis, the European Society of Cardiology (ESC) guidelines recommend 
using the ‘rule-in’ and ‘rule-out’ algorithms. NSTEMI can be ruled-out either 
by a low level of high-sensitivity troponin (hs-cTn) already upon presentation 
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or within 1 hour if no relevant increase in hs-cTn is detected. To rule-in for 
NSTEMI, hs-cTn should be either at least moderately elevated at the zero hour, 
or a clear increase in the hs-cTn levels at one hour should be observed. High-
sensitivity cardiac troponins allow the monitoring period between blood 
samples to decrease from three hours to one hour.117 Furthermore, high-
sensitivity troponins can even be used as point-of-care samples in emergency 
room settings without necessitating a central laboratory.126  
The definition of MI has evolved in recent decades.121 The latest universal 
definition of MI separates a myocardial injury as a unique entity. Based on this 
definition, the term myocardial injury should be used when evidence appears 
of elevated cardiac troponin values with at least one value falling above the 
99th percentile of the upper reference limit. Injury is considered acute if a rise 
and/or fall occurs in the troponin values. The term acute myocardial infarction 
(AMI) should instead be used if the previous criteria accompany at least one 
of the following: symptoms of myocardial ischemia, new ischemic ECG 
changes, the development of pathological Q waves in ECG, imaging evidence 
of a new loss of viable myocardium or a new regional wall motion abnormality 
in a pattern consistent with an ischaemic aetiology or the identification of a 
coronary thrombus through angiography or autopsy.123 MI falls into five 
different classifications based on the cause of the ischemia and prognostic 
differences. Compared to type 1 with a thrombus in the coronary lumen, type 
2 is defined by an imbalance between myocardial oxygen supply and demand 
unrelated to thrombosis. A type 3 MI occurs if a patient with symptoms 
suggesting myocardial ischemia dies before the myocardial injury was 
established, relying on biomarkers or later during an autopsy. Types 4 and 5 
are procedure-related MIs, for percutaneous coronary intervention (PCI) and 
coronary artery bypass grafting (CABG), respectively. 
After the initial diagnosis followed by primary medical treatment, a 
coronary angiography (CAG) both confirms the diagnosis as well as is used to 
treat the culprit of the cardiac event if indicated. For NSTE-ACS patients, the 
necessity and timing–immediate (<2 h), early (<24 h) and invasive (<72 h)–
of invasive CAG should be based upon individual risk stratification. For 
STEMI patients, an immediate diagnostic CAG combined with 




Figure 2 Diagnostic and treatment patterns of acute coronary syndrome.  
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CAG, coronary angiography; ECG, electrocardiogram; LBBB, left-
bundle branch block; NSTE-ACS, non-ST-elevation acute coronary syndrome; 
NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction; UA, unstable angina 
pectoris. Data adapted partially from White et al. 2008 with permission from 
Elsevier.127 
2.1.5 TREATMENT 
From the initial medical contact, ACS treatment runs parallel to both 
diagnostics and risk assessments (Figure 2). Differentiating between NSTE-
ACS and STEMI remains crucial since revascularisation of the occluded artery 
in STEMI should be performed as quickly as possible. In STEMI, the decision 
regarding the appropriate reperfusion therapy should also be made quickly. 
Primary PCI preferably with a drug-eluting stent to the culprit lesion through 
radial access represents the first-line treatment of choice if possible, within the 
first two hours. STEMI patients should be immediately transferred to the 
cathetrisation laboratory from the field to minimise any delay in definite 
treatment. In centres caring for STEMI patients, this logistical and therapeutic 
algorithm should be established, reviewed and taught regularly.  If primary 
PCI is not available within 120 min of diagnosing STEMI, thrombolysis, 
preferably at the incident site, followed by control CAG with the opportunity 
for rescue PCI serves as the second-best treatment option. For thrombolysis 
strategy, symptoms should not last longer than 12 h and contraindications 
should be absent. The efficacy of fibrinolysis decreases as the time from the 
onset of symptoms increases. Therefore, primary PCI should be considered as 
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an option if a patient presents late, particularly more than 3 h after sypmtom 
onset. After the initiation of thrombolysis, the patient should be transferred to 
a PCI centre, where CAG and PCI if indicated should be performed within 2 to 
24 h of successful lysis.116 If there are signs of unsuccessful fibrinolysis 
(recurrence of ST elevation and ongoing ischemic symptoms), immediate 
rescue PCI is indicated.128 Typical findings for succesfull thrombolysis are 
>50% resolution in the ST segment within 60 to 90 min, reperfusion 
arrhythmia and the disappearance of chest pain. 
For NSTE-ACS patients, the timing of CAG is based on an individual risk 
assessment depending upon symptoms and findings. CAG timing can vary 
from immediately to up to 72 hours. An immediate invasive strategy (CAG 
performed within 2 h) is indicated if an NSTE-ACS patient’s risk is estimated 
as very high based on the ESC guidelines. The criteria for a very high-risk 
situation include amongst others haemodynamic instability, life-threatening 
arrhythmias and acute heart failure. If ST- or T-wave changes are dynamic, a 
rise or fall in troponins occurs or the Global Registry of Acute Coronary Events 
(GRACE) score exceeds 140, the patient is characterised as high risk and an 
early invasive strategy is recommended, where CAG is undertaken within the 
first 24 h. The maximum CAG delay for patients identified as needing an 
invasive strategy (intermediate risk) is 72 h. Intermediate risk factors include 
DM, renal insufficiency, LVEF <40%, prior PCI or CABG or a GRACE score 
between 110 and 139. A patient is characterised as low risk if they present with 
none of the above risk criteria, and an invasive strategy is indicated only in 
select situations if symptoms recur. Otherwise, a noninvasive stress test is 
recommended.117 If the culprit lesion is anatomically unsuitable for PCI or a 
patient’s haemodynamic situation is compromised due to, for instance, 
cardiogenic shock or a mechanical complication from MI, emergent CABG 
should be performed for AMI patients. However, given the limited evidence, 
the timing of nonemergent CABG for stabilised post-MI patients should be 
determined on an individual basis. Yet, a washout period of 3 to 7 days after 
discontinuing the adenosine diphosphate receptor (ADP) inhibitor from a dual 
antiplatelet therapy (DAPT) is recommended for both STEMI and NSTE-ACS 
patients.116,117 
Contrary to differences in the revascularisation strategies between STEMI 
and NSTE-ACS patients, the standard medical care for both remains rather 
similar. According to various guidelines, antithrombotic therapy for an ACS 
patient irrespective of their final diagnoses comprises DAPT with aspirin and 
an ADP-receptor inhibitor (ticagrelor, prasugrel or clopidogrel) combined 
with a parenteral anticoagulant, whereby enoxaparin represents the drug of 
choice in Finland.116-119,129,130 Aspirin should be given as soon as possible on 
site following the initial diagnosis. It is typically administered orally, although 
intravenous administration might offer quicker and a more complete effect on 
inhibiting platelet aggregation and thromboxane generation.131 Although 
somewhat limited evidence exists for it, the early initiation of ADP inhibitors 
is also indicated.132,133 Clopidogrel formerly represented the first-line 
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treatment as an ADP inhibitor in ACS treatment, but has recently been 
outpaced by faster acting ticagrelor and prasugrel with superior outcomes and 
greater potency.134-136 Whilst accompanying a slightly higher risk of bleeding, 
if not contraindicated, those are now preffered ADP inhibitors (followed by 
clopidogrel) in ACS irrespective of the initial treatment strategy outlined in 
most recent guidelines.130,137,138 However, for STEMI patients treated for 
thrombolysis, clopidogrel remains the recommended ADP inhibitor.129 
Ticagrelor and prasugrel have not been investigated in conjuction with 
thrombolysis and, therefore, should not be used for fibrinolysed patients.  
When it comes to anticoagulation in ACS patients, slight differences exist 
in the guidelines. Finnish guidelines recommend low molecular–weight 
heparin—namely, enoxaparin—as the drug of choice for both NSTEMI and 
STEMI patients.139,140 However, European guidelines emphasise the routine 
use of unfractioned heparin, whilst enoxaparin and bivalirudin (a direct 
thrombin inhibitor) serve as alternative options for anticoagulation in STEMI 
patients. For NSTE-ACS patients receiving medical treatment, the ESC 
guidelines recommend fondaparinux (a selective factor Xa inhibitor) before 
enoxaparin as a first-line anticoagulation agent. Finnish guidelines 
recommend case-specific consideration of a glycoprotein IIb/IIIa inhibitor for 
patients undergoing PCI. 
Other conjunctive medical therapies used for both acute and long-term 
treatment of ACS consist of pain killers (namely, opioids titrated intravenously 
in an acute setting), -blockers, nitrates, angiotensin-converting enzyme 
(ACE) inhibitors and statins. In an acute setting, -blockers can be used both 
orally and intravenously (recommended) to control tachychardia and ischemic 
symptoms in the absence of signs of heart failure (HF), the development of 
cardiogenic shock or other contraindications. A randomised controlled trial 
(RCT) performed in 2005 found that an early intravenous β-blocker in AMI 
patients decreases the risk of reinfarction and ventricular fibrillation, but 
increased the risk of cardiogenic shock significantly.141 Since then, multiple 
studies have reported somewhat similar findings.142-144 Guidelines recommend 
the early administration of a -blocker with appropriate caution to both 
NSTEMI and STEMI patients within the first 24 hours in the absence of 
contraindications. For haemodynamically stable STEMI patients, the 
intravenous administration of a -blocker seems useful.116-119 However, the 
definitive role of and effect on prognosis of -blockers in acute treatment 
remain inconclusive, although early initiation seems to associate with both 
improved short- and long-term outcomes.145,146 Nitrates appear not to affect 
survival or prognosis amongst AMI patients, but are administered to reduce 
ischemic symptoms, especially in patients with high blood pressure upon 
admission.147 Furthermore, guidelines recommend the early initiation and 
continuation of intensive statin therapy to all ACS patients irrespective of their 
lipid profile.93,148-150 In addition, statins have undeniably improved the 
prognosis of ACS patients in both short- and long-term follow-up.151-153 ACE 
inhibitors or if ACE inhibitors are not tolerated angiotensin receptor blockers 
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(ARB) should also be initiated within the first 24 hours and continued, 
particularly for patients with any of the following: hypertension, DM, HF, left-
ventricular ejection fraction (LVEF) under 40% or chronic kidney disease 
(CKD).103,147,154-159 
2.1.6 SECONDARY PREVENTION 
Despite the impressive achievements in treating ACS patients, these 
individuals remain at an elevated risk for recurrent MI and both all-cause and 
cardiac-specific mortality following an ACS event.160-166 The elevated risk for 
both recurrent MI and death appears last indefinitely, although slightly 
decreases each subsequent year following an ACS event.61,167 This risk, 
estimated based on the individual’s risk profile, depends on multiple factors, 
most of which can be treated.168 Secondary prevention is based on both 
changes to a patient’s habits, such as exercising, weigth loss, smoking 
cessation and diet, but specifically relies on secondary prevention 
medications.15,169 Treatment focuses on the same risk factors as primary 
prevention, although medical therapies play an even larger role in secondary 
risk reduction.90,170 It is recommended that CV risk amongst ACS patients is 
evaluated annually following a cardiac event, even in asymptomatic cases. 
During the first year, at least two visits are recommended.171 A recent 
observational study demonstrated that, although the prognosis for high-risk 
patients specifically has recently improved, such patients remain undertreated 
using secondary prevention medications.172 Table 1 summarises the goals of 




















Table 1. Risk factor targets and primary recommended therapies following ACS 
according to European guidelines. Abbreviations: BMI, body mass index; 
CCB, calcium channel blocker; GLP1-R, glucagon-like peptide-1 receptor; LDL-
C, low-density lipoprotein cholesterol; RAA, renin-angiotensin-aldosteron; 
SGLT2, sodium-glucose co-transporter 2. Data adapted from ESC 
guidelines.90,91,103,108,116,117,171 
Risk factor Target Primary recommended therapy 
LDL-C 





If well-tolerated, <130/80 mmHg 
1. RAA inhibitor + -blocker/CCB 
2. CCB + diuretic/-blocker 
3. -blocker + diuretic 
Diabetes HbA1c < 7% 
1. SGLT2 inhibitor 
2. GLP1-R agonist 
Body weight 
BMI: 20–25 kg/m2 
Waist: <94cm (men) 
<80cm (women) 
Diet, exercise, behavioural modifications 
Smoking No exposure at all 
1. Follow-up support 
2. Nicotine replacement  
3. Varenicline, Bupropion 
Diet 
Healthy: low in saturated fat and salt, 




≥150 min/week moderate or 
≥75 min/week vigorous aerobic 
Prescribed physical activity 
 
 
One of the major secondary prevention therapies following ACS is DAPT, 
consisting of both aspirin and an ADP (P2Y12) inhibitor. Currently, guidelines 
recommend ticagrelor or prasugrel over clopidogrel; yet, by the time we 
recruited our cohort, clopidogrel stood as the drug of choice for all patients. 
For STEMI patients treated with primary PCI, treatment with DAPT should 
continue for 12 months.116,119 For STEMI patients treated with fibrinolysis, 
European guidelines recommend (published 2017) extending DAPT for only 
one month if subsequent PCI is not performed (although expanding the 
duration to 12 months should be considered), and for 12 months if it was.116 
Published also in 2017, a European-focused update on DAPT recommends a 
12-month treatment duration for all ACS patients without a high risk for 
bleeding, whether treated only medically with PCI or CABG, a 
recommendation similar to that for NSTE-ACS.117,129 In addition, a US-focused 
update on the duration of DAPT published in 2016 by the American Heart 
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Association (AHA) and the American College of Cardiology (ACC) 
recommends a 12-month course of DAPT for all ACS patients, regardless of the 
acute treatment strategy.130 For thrombolysed patients, all guidelines continue 
to recommend clopidogrel. For patients at a substantial risk for bleeding, a 
shortened therapy length of six months should be considered in both STEMI 
and NSTE-ACS, specifically if a drug-eluting stent was used for 
revascularisation. In addition, a concomitant proton pump inhibitor should be 
administered to patients at an increased risk of gastrointestinal bleeding. 
Following DAPT, aspirin should be used indefinitely and the continuation of 
DAPT as a long-term secondary prevention strategy for high-risk patients 
should be considered.116,117,129,130,137,171 For ACS patients with a verified 
indication for oral anticoagulation (OAC), such as atrial fibrillation, 
mechanical heart valve or venous thromboembolism, triple therapy concisting 
of aspirin, clopidogrel and either NOAC or Warfarin should be used for up to 
six months, after which a dual therapy consisting of either an OAC/clopidogrel 
or aspirin/clopidogrel combination should be used for up to 12 months. After 
one year, only OAC is continued. If bleeding risks outweigh the ischemic risks, 
a triple therapy for only one month or a dual therapy with clopidogrel and OAC 
should be considered.129  
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors 
or statins have unquestionably proven to decrease both short- and long-term 
mortality as well as the incidence of recurrent MI amongst post-ACS 
patients.151 Guidelines encourage the early initiation of intensive statin therapy 
to all ACS patients irrespective of their lipid profile.91,93,116-119,148,149 Based on 
the most recent European guidelines, statin therapy aims to achieve an LDL-
C level <1.4 mmol/l or a 50% reduction if baseline LDL-C lies between 1.4 and 
3.5 mmol/l. In post-ACS patients, the key message regarding LDL-C remains 
‘the lower the better’.100,173,174 In Finland, the recommended target LDL-C in 
post-ACS patients remains <1.8 mmol/l, although national guidelines will 
likely become more strict in the near future in order to agree with European 
guidelines.175 In the rare case of statin intolerance, ezetimibe should be 
considered as an optional lipid-lowering therapy. In addition, ezetimibe 
should be combined with high-intensity statin therapy if the LDL-C target level 
is not achieved after four to six weeks of treatment with a statin alone.91,176 
Furthermore, if this combination remains insufficiently effective, adding a 
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor—namely, 
evolocumab and alirocumab—is the final option. These represent the latest 
lipid-lowering medications on the market proven to lower the LDL-C 
concentration and, therefore, holding prognostic value.177,178 The importance 
of statin therapy and specifically adherence to it are discussed in more detail 
below. 
Despite the most significant evidence dating to the prereperfusion era, -
blockers are still used in the secondary prevention for CAD following ACS. 
European guidelines recommend a continuous -blocker for all STEMI 
patients and those NSTE-ACS patients suffering from HF, arrhythmia or with 
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lowered LVEF. US guidelines recommend permanent -blocker therapy for all 
MI patients other than those without HF or hypertension, for whom three 
years of treatment is considered sufficient.116-119 The inconclusive role of -
blockers as a secondary prevention is addressed further below. 
European guidelines recommend considering an angiotensin-converting 
enzyme (ACE) inhibitor for all STEMI patients, whilst strongly recommending 
one for both STEMI and NSTE-ACS patients with HF, LVEF under 40%, 
hypertension or diabetes.116,117,147,155 As an individual risk factor for CAD and, 
thus, ACS, hypertension should be treated effectively to reach a target blood 
pressure of <130/80 mmHg amongst ACS patients. The algorithm in the ESC 
hypertension guidelines for the medical treatment of hypertension amongst 
CAD patients varies depending on the grade of hypertension and concomitant 
conditions (i.e., HF, atrial fibrillation and CKD), but is typically based on at 
least two agents in one pill initially (e.g., ACE inhibitor + -blocker).103 Recent 
European guidelines on stable coronary disease recommend an ACE inhibitor 
or ARB combined with a -blocker for recent MI patients with hypertension.171 
In addition, DM represents a substantial independent risk factor of CAD 
and ACS, whereby diabetic patients with CAD are considered very high-risk 
patients. Roughly 20% of CAD patients are previously diagnosed with DM, 
whilst prediabetes is even more common amongst both CAD and ACS patients. 
The targeted glycated HbA1c level for CAD patients should fall <7%. This can 
be achieved using both lifestyle management and tailored medical 
therapies.108,171 The most conclusive evidence on reducing CV events and 
deaths amongst diabetic CAD patients results from sodium-glucose co-
transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor 
agonists (GLP1-RAs), explaining their role as first-line recommendations 
followed by metformin.108 
In addition to secondary preventive medical therapies, the prognosis for 
select ACS patients can also be improved by preventing an SCD caused by fatal 
arrhythmias using an implantable cardioverter defibrillator (ICD). ICD is 
recommended for the long-term management of ventricular arrhythmias 
amongst ACS patients with symptomatic heart failure and LVEF <35% despite 
optimal medical therapy for at least 3 months. At least 6 weeks should lapse 
from the event and the patient’s expected survival should be at least 1 year in 
order to be eligible for an ICD implantation.116 
2.2 STATINS 
Given that the most important factor in the development of coronary artery 
plaque, and subsequently CAD, lies in the retention of LDL-C within the 
intimal layer of the artery wall, the most important prevention and treatment 
agents target lowering the concentration of LDL-C.99 HMG-CoA reductase 
inhibitors or statins are the cornerstone medications in this instance, although 
other promising lipid-lowering therapies have recently emerged, which are 
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primarily utilised in tandem with statins to reduce LDL-C as much as 
possible.177,178 The role of statins in secondary prevention following ACS was 
well-established long before our study. However, the effect of nonadherence 
on ACS patients’ long-term survival remained scarcely investigated.16,179-181 
2.2.1 PHARMACOLOGY 
Statins inhibit HMG-CoA reductase, a rate-limiting enzyme in synthesising 
cholesterol in the liver. This reduces the intracellular concentration of 
cholesterol, which in turn promotes LDL-receptor expression on the cell 
membrane leading to the increased intake of LDL-C, eventually resulting in 
lowering the LDL-C concentration in the blood stream.182 In this way, statins 
can reduce the LDL-C level by more than 50% from baseline, depending on the 
dosage administered.91 In addition to being dose-dependent, a reduction in 
LDL-C is individual to which multiple genetic factors are also known to 
contribute.173,183  
Although their primary effect is mediated through a reduction in LDL, 
statins carry positive albeit relatively minor effects on other lipids, such as 
HDL, triglycerides (TG) and Lipoprotein(a) [Lp(a)] as well.184,185 In addition, 
the pleiotropic effects, such as antiinflammatory and antioxidant effects, have 
gained much attention given their discovery from in vitro studies, although 
their clinical meaning in CAD prevention remains inconclusive.186,187 
In general, statins are very well-tolerated, but might cause specific adverse 
effects, of which the most feared whilst rare (1–3 cases/100 000 patient-years) 
is rhabdomyolysis.188 More common adverse events include myopathy, 
elevation in the liver enzymes and the incidence of new-onset DM.182,189 Statins 
can be categorised in many different ways, for instance, through their potency 
in lowering LDL-C, their chemical derivation (synthetic or fermentation), their 
lipo- vs. hydrophilic properties and their metabolism via different cytochrome 
enzymes [such as cytochrome P (CYP), to name a few].190,191 These agent-
specific characteristics amongst others affect both the potency in reducing 
LDL-C, but also the tolerability, possible adverse effects and interactions 
related to different statins.182 Many drug–drug interactions have been 
observed with statins, primarily related to metabolism via CYP3A4, whilst 
many other CYPs are also involved.91 In Finland, simvastatin, lovastatin, 
pravastatin, fluvastatin, atorvastatin and rosuvastatin are currently available 
on the market. Amongst these, the most-used statin during the recruitment of 
our study cohort was simvastatin, followed by atorvastatin and rosuvastatin.192 
2.2.2 LONG-TERM USE OF STATINS FOLLOWING ACS 
Following their introduction to the market for the treatment of 
hypercholesterolaemia in the 1980s, researchers amassed much evidence on 
the impact of statins on coronary patients’ survival. Multiple meta-analyses 
from randomised controlled trials (RCTs) have demonstrated their efficacy on 
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both stable CAD as well as ACS patients.151,174,193-197 In 2010, large meta-
analyses concluded that a 20% reduction in CAD mortality accompanied each 
1 mmol/l reduction in the LDL-C concentration comparing statin to no statin 
or high-intensity to low-intensity treatment.93 Amongst ACS patients, 
guidelines recommend both early initiation and life-long high-intensity statin 
therapy. 148,149,152 Whilst cholesterol levels should be measured for risk 
assessment and further follow-up, statin therapy is indicated for every ACS 
patient regardless of lipid levels.90,91,116,117 Statins also reduce the incidence of 
new HF amongst CAD and ACS patients.198,199 Whether patients with HF but 
not CAD benefit from statins remains debatable, although a recent systematic 
review concluded that statins may improve CV outcomes amongst all HF 
patients, irrespective of their LVEF level and their HF aetiology.200 However, 
two prior RCTs and a meta-analysis concluded that amongst HF patients no 
clear benefit results from statins in terms of CV mortality.201-203 
Prior to our statin study, issues regarding adherence to secondary 
prevention therapies, specifically to statins, were observed.180,181,204 
Furthermore, in Finland at the beginning of the preceding decade, statins 
received unjustified negative media coverage, impacing public opinion on 
statins. Misinformation regarding their alleged adverse effects also spread.205  
In separate studies, 5% to 20% of ACS patients did not initiate statin 
therapy following discharge, with another 13% discontinuing its use at 6 
months. In addition, the adherence rate decreased during the follow-up, 
falling to about 40% to 75% at the 1- to 2-year mark, further falling to as low 
as 26% to 49% at the 5-year follow-up mark.15,16,18,20,179,206,207 In a study 
analysing the persistence of statin therapy amongst new statin users in 
Finland, only 43.9% of patients remained adherent after 10 years.19 However, 
the rate of statin discontinuation during the first year following treatment 
initiation decreased at least up to 2004 compared with discontinuation levels 
from 1995 initiators, in Finland.208 Moreover, alongside increased in-hospital 
statin use, guidelines were generally better followed in 2003 than in 2001 
based on the FINACS (Finnish Prospective Nation Wide Study on Acute 
Coronary Syndrome) I and II studies amongst NSTE-ACS patients.209    
A discrepancy in the adherence rates comparing clinical trials and real-life 
practice was also noted.210,211 Multiple factors affecting nonadherence, 
including genuine side effects, polypharmacy, viewing a medication as 
unnecessary and even the prescriber’s personality, were identified. Proposals 
aimed at improving adherence were also investigated.180,207,212,213 A delay in 
filling the first statin prescription following hospitalisation for ACS was 
identified as one indicator of a greater risk for future nonadherence.214  
By the time of our study, however, the impact of nonadherence to statins 
on ACS patients’ long-term mortality was rarely assessed.17,20,215 Yet, these 
studies consistently reported around a 25% to 40% increase in the relative risk 
for all-cause mortality with nonadherence to statins. Moreover, meta-analyses 
identified an increased mortality with nonadherence to a placebo, both 
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highlighting the complexity of adherence per se as well as demonstrating the 
existence of a healthy adherer bias in adherence studies.216  
After our study, several studies have assessed adherence to secondary 
prevention medications following ACS, reporting somewhat similar findings, 
regarding statin therapy, than studies conducted prior to ours.217-223 
Interestingly, however,  a Cochrane review published in 2014 claimed that the 
initiation of statin therapy within 14 days of ACS onset rather than reducing 
unstable angina did not reduce mortality, stroke incidence or recurrence of MI 
within the first four months of use.224 However, the authors noted that the 
prognostic effects of statins probably manifest only later than 4 months 
following ACS. In a European multicentre survey, on average about 85% of 
CAD/ACS patients used a statin at the follow-up interview, a median of 1.35 
years after the index event of PCI, CABG or ACS. However, a marked variation 
in statin adherence between countries was observed, ranging from 73.5% to 
96.1%, whereby Finland clearly fell below the average at 81.9%.225 The 1-year 
adherence rate to statins following ACS, measured as MPR >80% based on the 
defined daily dose (DDD), differed significantly between US and Hong Kong 
cohorts at 78.2% and 90.0%, respectively.  
Interventions aimed at improving adherence have also been examined 
further. A Swedish RCT found that nurse-based medical titration and follow-
up led to better long-term adherence than standard care amongst ACS 
patients.226 Similar findings were reported in an analogous Indian RCT.227 In 
a Canadian RCT amongst STEMI patients, however, an automated reminder 
urging long-term use of guideline-recommended medications did not improve 
adherence.228 A Swedish registry study concluded that one possible 
explanation for worse adherence to both guidelines by physicians and to 
medications prescribed to ACS patients could stem from impaired renal 
function.229 Moreover, a large US registry study found that a statin was 
prescribed less frequently to diabetic compared to nondiabetic patients upon 
discharge following ACS.230 Amongst patients with chronic obstructive 
pulmonary disease, statins along with -blockers and aspirin were also 
underutilised when compared to patients without disease. In that Danish 
study, a profound increase in statin use from 1995 to 2015 was generally 
observed.231  
 
2.3 BETA BLOCKERS 
Since their discovery in the 1960s, -blockers have played a crucial role in 
standard medical regimens to treat both stable CAD and ACS patients. In 
addition, hypertension and arrhythmias alone have been treated using -
blockers for decades. For some time, they have also been used to treat heart 





The treatment effect of -blockers is mediated by their antiischemic, 
antiarrhythmic and antihypertensive properties. These properties result from 
the binding of a -adrenergic antagonist to -adrenoceptors, producing an 
antagonistic effect from the -adrenergic stimuli caused by adrenalin and 
noradrenalin in various tissues and organs in the body. This antagonism is 
reversible and competitive. Thus, -blockers both decrease the heart rate and 
cardiac contractility more effectively particularly when the sympathetic 
nervous system is activated, such as during exercise. Following an MI, -
blockers were shown to improve ventricular remodelling, prevent fatal 
arrhythmias and, most of all, decrease oxygen demand from the 
myocardium.232 
-blockers have been classified as (cardio-) selective and nonselective 
based on their binding properties to -adrenergic receptor types 1 (mainly 
expressed in the heart tissue) and 2 (also expressed in, for instance, the blood 
vessels, gastrointestinal tract and lungs). Selective, second-generation 1-
blockers have a higher affinity to the 1 receptor, since nonselective first-
generation -blockers bind to both receptors at a similar magnitude. This 
selectivity depends on the dosage and is lost at higher doses. Currently, 
cardioselective -blockers are preferred, although nonselective -blockers 
remain relevant in certain settings.232  
-blockers are generally well-tolerated, although they may naturally cause 
adverse effects particularly when used in larger doses. The most common 
adverse events include cardiovascular events, such as bradycardia and 
Raynaud’s phenomenon, as well as more general effects including fatigue, 
headaches and insomnia and the impairement of sexual function stemming 
from the loss of libido or aggravating impotence. -blockers, especially 
nonselective β-blockers, can also mask the symptoms of hypoglycaemia (e.g., 
tachycardia and tremours) amongst insulin-dependent diabetic patients. In 
addition, -blockers may increase airway resistance, causing a life-threatening 
situation, such that asthma and bronchospastic obstructive pulmonary disease 
represent relative contraindications for initiating -blockers. Absolute 
contraindications for -blockers include symptomatic hypotension or 
bradycardia and severe decompensated heart failure.232  
As early as the 1970s,  clinicians recognised that the abrupt 
discontinuation of long-term -blocker therapy may exacerbate angina, acute 
myocardial infarction or even sudden cardiac death.233,234 This -blocker 
withdrawal syndrome was thought to arise from a -adrenergic 
hypersensitivity acquired during the long-term use of -blockers. During long-
term treatment, the number of -adrenergic receptors expressed appeared to 
increase in the myocardium and, if the -blocker was abruptly discontinued 
without a stepwise decrease in the dosage, the effect of adrenergic agents—for 
example during exercise—could overwhelm the myocardium due to the 
increased sensitivity to them.235 Several studies conducted during the pre-
reperfusion era showed a marked deterioration in a patient’s condition, 
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tachycardia, a decrease in EF and blood pressure elevation amongst patients 
with previous CAD or heart failure when they discontinued -blockers.234,236 
However, a study from the 1980s concluded that the withdrawal syndrome was 
not clinically important amongst AMI patients, whereby their -blocker could 
be abruptly discontinued if indicated.237 A more recent study suggested that 
the withdrawal syndrome was associated with an increased risk of MI only 
with cardioselective -blockers.238 However, given the possibility of rebound 
symptoms, if necessary, long-term -blocker therapy should be gradually 
discontinued through a stepwise decrease in the daily dosages. 
 
2.3.2 LONG-TERM USE OF Β-BLOCKERS FOLLOWING ACS 
Most studies affirming the role of continuous -blocker therapy following MI 
predate routine reperfusion therapies.239 Conclusive evidence from the 
reperfusion era, however, remains lacking.21 Yet, continous -blocker therapy 
is recommended in ESC guidelines for all STEMI patients irrespective of their 
cardiac function when no contraindications are present. As a class I 
recommendation with level-A evidence, -blockers are indicated for patients 
with HF and/or LVEF ≤40%, whilst a class IIa recommendation with level-B 
evidence provides for routine -blocker consideration for all STEMI 
patients.116 For NSTE-ACS patients with preserved cardiac function, however, 
routine -blocker therapy is no longer recommended.117 Yet, the need for 
further studies examining β-blocker use in patients with normal or mildly 
lowered LV function is outlined in the guideline. For NSTE-ACS patients with 
LVEF under 40%, -blockers are also recommended. Moreover, the latest US 
guidelines continue to recommend life-long -blocker therapy for all post-MI 
patients, although amongst patients without HF or hypertension, 3 years of -
blocker therapy might be sufficient.118,119,240 Based on previous evidence 
suggesting a reduction in mortality accompanying carvedilol, metoprolol, 
bisoprolol and nebivolol, only these agents are recommended.22,241-246 
As the recommendations in guidelines indicate, recent observational 
studies have identified the most prominent association from the benefits 
associated with -blockers following MI amongst high-risk patients, that is, 
patients with lowered LVEF, a history of prior MI or multivessel disease.247-251 
In these studies, follow-up lasted from six months to nearly four years. 
Furthermore, both Dondo et al. and Puymirat et al. concluded in their recent 
studies that MI patients without HF do not exhibit a lower mortality from 
long-term -blocker therapy.26,30 In a subgroup of previous MI patients from 
a large observational study, -blocker therapy did not associate with a lower 
risk of composite cardiovascular events. However, other recent studies found 
an independent reduction in one-year mortality associated with -blocker 
therapy amongst all ACS patients regardless of their risk profile.25,32,252,253 
Furthermore, a meta-analysis of STEMI patients treated with PCI identified 
an association between lower all-cause mortality and -blockers amongst 
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patients with preserved  LVEF.27 Additionally, a recent retrospective study  
with propensity score matching also identified an association between -
blocker use and decreased long-term mortality in a lengthy five-year follow-
up amongst ACS patients with preserved cardiac function.31 Another 
observational study amongst patients with a first MI linked long-term -
blocker therapy with a lower rate of recurrent MI and all-cause mortality with 
a follow-up extending to at least 3.7 years.24 Furthermore, two more recent 
publications, a meta-analysis and a cohort study recommended long-term -
blocker use for all ACS patients including low-risk patients, even one year 
following a cardiac event.28,29 Yet, again, a recent systematic review claimed 
that discontinuing the -blocker therapy one year after an MI amongst 
patients with preserved LV function would be reasonable if no other 
indications for its use existed.33 This finding was supported by a more recent 
observational study amongst MI patients over 65 years old for whom no 
benefit was found from -blocker use three years following an MI.34 
Only a few RCTs have been performed in the reperfusion era on the 
long-term use of -blockers. The Carvedilol Post-Infarction Survival Control 
in the Left-Ventricular Dysfunction (CAPRICORN) trial demonstrated that 
carvedilol therapy reduced both the recurrence of MI and long-term mortality 
amongst patients after an MI complicated by LV dysfunction.22 Moreover, the 
recent Carvedilol Post-Intervention Long-Term Administration in Large-Scale 
Randomised Controlled Trial (CAPITAL-RCT) suggested that low-risk STEMI 
patients would not benefit from long-term carvedilol therapy following PCI.23 
Unfortunately, this study was evaluated as underpowered and, thus, carried a 
limitation in the generalisability of the findings. However, these few RCTs 
support the idea of a limited benefit from -blockers for low-risk patients 
following an ACS event. 
Still, evidence for or against the long-term use of -blocker therapy 
following ACS, particularly for low-risk patients with preserved LV function, 
remains inconclusive. This might be one of the reasons why adherence to -
blocker therapy amongst other secondary preventive medications is quite 
poor. Wide variation exists in the adherence to guidelines by physicians.254,255 
Overall, adherence to -blockers decreases with time following an ACS event. 
15,228,256 High-risk patients appear to adhere to medication use more poorly, 
which is particularly alarming.257 Few studies have examined the effect of 
adherence to secondary prevention medications on long-term survival. 
Hamood et al. found that nonadherence to -blockers, as opposed to other 
medications, did not affect all-cause mortality amongst post-MI patients.258 
Yet, in a study of both MI and non-MI patients following CABG, inconsistent 
or nonuse of -blockers increased mortality when compared to regular use.259 
After the 1990s, examinations of -blocker withdrawal syndrome are 
scarce and solid evidence from RCTs of its effect on ACS patient survival 
remains lacking.260 However, the phenomenon is real and to some extent 
might explain worse outcomes amongst nonadherent ACS patients in some 
studies.  
Review of the literature 
34 
 
2.4 NONSTEROIDAL ANTIINFLAMMATORY DRUGS 
(NSAIDS) 
NSAIDs are the most commonly used painkillers worldwide. They are broadly 
utilised for multiple purposes because of their analgaetic, antipyretic and 
antiinflammatory effects.35 However, NSAIDs are also well known for their 
adverse gastrointestinal and renal effects.261,262 Their harmful effects on the 
cardiovascular system, including the elevation of blood pressure, fluid 
retention and, therefore, an increased risk of exacerbating heart failure, were 
also discovered long ago.263,264  Growing evidence of unfavourable outcomes—
namely, an increased risk of MI on both stable CAD and ACS patients—has 
emerged within recent decades as well.36,265,266 
 
2.4.1 PHARMACOLOGY AND ADVERSE CARDIOVASCULAR 
EFFECTS 
NSAIDs inhibit the cyclooxygenase (COX) enzyme, which has two different 
isoforms, COX-1 and COX-2. Both isoforms produce prostaglandin H2 (PGH-
2) from arachinodic acid, whereby PGH-2 is, in turn, converted to prostanoids, 
more specifically, thromboxanes, prostacyclins and prostaglandins, by 
different enzymes depending on the tissue. These prostanoids mediate 
different bodily functions, including the protection of gastric mucosa by 
prostaglandin E2 (PGE-2) and prostacyclin (PGI-2) produced by COX-1. In 
turn, PGE-2 formed by COX-1 in the kidneys participates in the regulation of 
glomerular filtration, whilst COX-2- generated PGI-2 affects renin secretion 
amongst others. Furthermore, both COX isoenzymes produce PGI-2 in the 
arteries, causing vasodilation and antithrombotic effects. In turn, 
thromboxane A2 (TXA-2) formed by COX-1 in thrombocytes antagonises the 
effects of PGI-2.267,268  
NSAIDs are classified as nonselective COX-1 and COX-2 inhibitors 
(acetylsalicylic acid, ibuprofen, diclofenac, ketoprofen, indomethacin and 
naproxen), preferential COX-2 inhibitors (meloxicam, nimesulide and 
etodolac) and selective COX-2 inhibitors (celecoxib, rofecoxib, etoricoxib and 
valdecoxib) based on their selectivity to the COX isoforms.267,268 
The cardiovascular, or more precisely thrombotic, adverse effects of 
NSAIDs are thought to stem from multiple factors and vary greatly between 
different NSAID agents.267-269 Whilst inhibiting COX-2 and, therefore, the 
formation of possibly cardioprotective PGI-2, nonselective NSAIDs also 
inhibit the production of thrombogenic and vasoconstricting TXA-2 by COX-
1. Selective COX-2 inhibition, however, leads to the decreased concentration 
of vasodilating and antithrombotic PGI-2, whilst the formation of harmful 
 
35 
TXA-2 remains uninhibited.270 This was the first mechanism hypothesised to 
increase the CV risks from selective COX-2 inhibitors, yet clearly not providing 
a complete explanation.271 It seems that the overall strength of COX-2 
inhibition is the primary factor contributing to the risk for the CV events from 
NSAIDs.272 The decrease in PGI-2 causes a thrombogenic state, elevates blood 
pressure and possibly leads to atherosclerosis. Other proposed mechanisms 
participating in the elevated CV risk include the inhibited effect of PGI-2 
towards resisting the ischemic-reperfusion injury to the myocardium and the 
inhibition of the cardioprotective effects from statins.273-276 Overall, however, 
the precise mechanisms of the cardiovascular adverse effects remain 
unknown. 
 
2.4.2 LONG-TERM RISKS AMONGST ACS PATIENTS 
Previously, the antiinflammatory and analgetic effects were assumed to be 
mediated only by the COX-2 isoenzyme, whilst COX-1 inhibition would lead to 
adverse gastric effects (a bleeding or perforated gastric ulcer representing the 
most serious). This led to the development of COX-2 selective NSAIDs, 
namely, coxibs. Several RCTs demonstrated the more favourable gastric 
properties of coxibs, whilst surprisingly and simultaneously discovering the 
increased risk of thrombotic events associated with their use, specifically with 
rofecoxib.37-41 This discovery also emerged in observational studies.36 In 2004, 
rofecoxib was voluntarily withdrawn from the US market because of the 
increased cardiovascular risks. In 2005, the European Medicines Agency 
contraindicated the use of coxibs in patients with ischemic heart disease.42 
Then, in 2007, a focused update from AHA discouraged the use of all NSAIDs 
in CAD patients.43 Since then, evidence has increasingly mounted. Today, 
amongst COX-2-selective NSAIDs, only celecoxib is available in the US, whilst 
in Finland etoricoxib is also prescribed. Recently, celecoxib was repeatedly 
proposed as noninferior compared to nonselective ibuprofen or naproxen 
regarding its CV safety profile.277-282 However, recent review articles 
thoroughly highlighted the limitations of celecoxib RCTs (SCOT and 
PRECISION), concluding that celecoxib’s safety over nonselective NSAIDs is 
far from established.268,283 In addition, recent observational studies have also 
summarised similar findings.284 
Recent studies associated NSAID use not only with a greater risk of both 
first-time and recurrent MI, but also with increased coronary, cardiovascular 
and all-cause mortality. 45,46,48,285-289 For MI patients, the risk of increased 
mortality appears to persist for several years following a cardiac event whereby 
not even the short-term use of NSAIDs is recommended.46,47 Moreover, using 
NSAIDs was also recently associated with an increased risk for stroke and 
atrial fibrillation.290,291 Given their mechanism of action, NSAIDs are thought 
to mediate their adverse effects on coronary patients through thrombotic 
complications. However, NSAIDs also increase the risk for bleeding, possibly 
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aggravated specifically amongst post-ACS patients receiving antiplatelet or 
anticoagulant therapies.48,292,293 Previous studies indicate that no NSAID 
irrespective of their selectivity is safe for CAD patients.47,286 Based on the 
available evidence, in addition to patients with established CAD, guidelines 
already recommend avoiding all NSAID use amongst those patients at an 
elevated risk for cardiovascular disease.117-119,275 Yet, despite clear evidence 
against them, NSAIDs remain quite commonly prescribed to and used by ACS 
and CAD patients.35,43,44,46,289,294 
 
2.5 RED BLOOD CELL (RBC) TRANSFUSION 
2.5.1 ANAEMIA AND BLEEDING AMONGST ACS PATIENTS 
Besides evaluating the risk of ischemic complications during acute treatment 
for ACS patients, risk assessment includes considering bleeding risk as well. 
Primarily stemming from highly effective antithrombotic therapy, 
anticoagulation and procedures performed (PCI and CABG), ACS patients are 
at greater risk of bleeding.9,10 Individual characteristics, such as an advanced 
age, female gender, renal insufficiency, hypertension and a history of previous 
bleeding, associate with an increased risk of major bleeding during an ACS 
event.295 To estimate the bleeding risk for an ACS patient, few risk scores have 
been developed.296,297 Due to their heterogeneity and lack of validation for any 
of the scores, a new definition for high bleeding risk was recently published by 
the Academic Research Consortium for High Bleeding Risk (ARC-HBR), 
which focuses on the risk assessment of patients undergoing PCI, whether in 
an acute setting or not.298 
Heterogeneous definitions of major bleeding has also been applied, partly 
explaining why the incidence of major bleeding complications varied greatly 
amongst ACS patients in prior studies, ranging from <1% to around 10%.10,299-
302 Moreover, the proportion of patients requiring RBC transfusions also 
varied from 4% to 30%.303 A position paper by ESC described several tools to 
define bleeding events: the Thrombolysis in Myocardial Infarction (TIMI) and 
the Global Utilisation of Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries (GUSTO) representing the most commonly used 
tools.304,305 Yet, to systematise both clinical use and reporting bleeding events 
in clinical trials using a validated method, the Bleeding Academic Research 
Consortium (BARC) definition of bleeding was developed.306,307 
Major bleeding has been independently associated with increased adverse 
outcomes (including recurrent MI, stent thrombosis and stroke), specifically 
with both short- and long-term mortality amongst ACS patients.10,295,301,308-313 
Several possible reasons explain this increased mortality caused by bleeding. 
In addition to possible ischemia caused by a lower blood volume and a 
reduction in oxygen delivery, the discontinuation of antithrombotic therapies 
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followed by the accretion of new thrombus in the coronary artery serves as one 
possible explanation.314,315 However, discontinuing antithormbotic therapy is 
recommended if bleeding leads to hypotension or is life-threatening.306 
Anaemia, defined by the World Health Organisation (WHO), occurs with a 
haemoglobin (Hb) concentration under 130 g/l in men and under 120 g/l in 
women.316 Even without bleeding, 10% to 43% of ACS patients are already 
anaemic at baseline.317 Independent of comorbidities, anaemia was repeatedly 
found to directly associate with an increased short- and long-term mortality 
amongst ACS patients.318-322 This relationship is most likely multifactorial, but 
one probable explanation is exacerbated myocardial ischemia, likely caused by 
decreased blood oxygen levels and increased myocardial oxygen demand due 
to a reactive increase in cardiac output.321 
  
2.5.2 RBC TRANSFUSIONS FOR ACS PATIENTS 
Both anaemia and bleeding have been treated for decades using RBC 
transfusion to replenish both the circulating blood volume and its oxygenative 
capabilities, eventually thought to minimise myocardial ischemia.11 However, 
in recent decades, an independent association between RBC transfusion and 
poorer outcomes both in general use and amongst ACS patients was found. 
Guidelines already recommend a restrictive (Hb target >80 or 70g/l) over 
liberal (Hb target >100g/l) transfusion strategy to all other patient subgroups, 
including stable CAD patients, except ACS patients.13,14,323  
Recent studies amongst ACS patients demonstrated somewhat 
controversial results on this topic. Only a few RCTs exist, with contradictory 
results. For instance, Cooper et al. concluded in their RCT that a liberal versus 
restrictive transfusion strategy associated with a poorer outcome amongst ACS 
patients.324 Yet, Carson et al. argued that a liberal strategy could even decrease 
mortality when compared to a restrictive strategy.325,326 However, RCTs 
conducted on critically ill patients in noncardiac settings linked a restrictive 
strategy to a better or at least similar survival compared to a liberal strategy.327-
330 Yet, in an RCT comparing a liberal to restrictive transfusion strategy 
following hip replacement surgery amongst patients at high CV-risk a liberal 
strategy did not affect long-term mortality.331  
Registry studies quite conclusively associated RBC transfusion or the 
liberal transfusion strategy with an increased mortality amongst ACS patients. 
This association was found for short-term in-hospital mortality for up to one-
year.303,332-336 Yet, the impact on long-term survival remains unclear. In some 
studies, however, RBC transfusion associated with either a neutral or even 
beneficial outcome related to in-hospital mortality.337,338 In a small 
retrospective study of non-ACS patients with a myocardial injury (diagnosed 
with troponin release), avoiding blood transfusion for patients with Hb <80 
g/l associated with a poorer outcome.339 In addition to mortality, RBC 
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transfusion associated with an increased risk for both adverse cardiac events 
and stroke following cardiovascular interventions.340,341  
A recent meta-analysis of observational studies from 1966 to 2016 
strenghtened the association of increased mortality and reinfarction rates with 
RBC transfusion therapy amongst ACS patients.342 Transfusion seemed 
beneficial or at least neutral amongst patients with Hb <80g/l, but detrimental 
amongst patients with Hb >100 g/l. Similar results were observed amongst 
elderly MI patients in a recent French study.343 In addition, a meta-analysis 
consisting of STEMI patients concluded that RBC transfusion increases 
mortality and morbidity amongst these patients, whereby the observed 
difference cannot be explained by comorbidities alone.344 Another rigorous 
meta-analysis conducted by Chatterjee et al. also demonstrated that RBC 
transfusion or a liberal strategy independently associated with an increase in 
all-cause mortality.345 However, aside from the one RCT (Cooper et al.) 
mentioned, this meta-analysis relied on observational studies, where both a 
bias in the association between the indication (anaemia or bleeding) and 
treatment as well as a bias from unmeasured confounding factors 
persisted.346,347  
 Due to this inconclusice evidence, guidelines have remained unable to 
determine best practice regarding RBC transfusion for anaemic or bleeding 
ACS patients.12 Yet, caution is recommended when treating ACS patients with 
transfusions. Based on the best available evidence, using RBC transfusion is 
justified when Hb <80 g/l and avoided when Hb >100g/l.317 Within that gray 
area, however, decisions must be made on a case-by-case manner. Moreover, 
preventive measures should be considered in order to minimise the risk of 
bleeding.308,348 This can be achieved by, for example, identifying vulnerable 
patients using risk assessment tools, reducing the dosage of antithrombotic 
agents and using radial instead of femoral access in coronary 
interventions.297,349-351 Since nonaccess-site bleeding associates with an even 
greater risk for adverse outcomes compared to access-site bleeding, the 
importance of other strategies to minimise bleeding, irrespective of the route 
of access, cannot be sufficiently emphasised.352,353 
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3 AIMS OF THE STUDY 
The primary aim of this study involved filling the gaps in our knowledge 
related to factors contributing to ACS patients’ long-term survival. More 
precisely, we aimed to identify medical behaviour and its effect on ACS 
patients’ survival and to study the effect of transfusions given in an acute 
setting on ACS patients’ long-term prognosis. The objectives of the four studies 
were as follows: 
 
 
1) To determine the utilisation rate of statins following an ACS event at 
Helsinki University Central Hospital (HUS) and to assess the effect of 
adherence to statins on ACS patients’ long-term mortality. 
 
2) To assess the effect of RBC transfusion administered during acute 
treatment on the long-term morbidity and mortality of ACS patients. 
 
3) To determine prescription filling and adherence rates to -blockers 
following ACS and to examine the effect of nonadherence to -blockers 
on ACS patients’ long-term survival.  
 
4) To elucidate the usage rate of prescribed NSAIDs and the effect of 








4.1 STUDY COHORT 
Between March 2006 and March 2008, all consecutive patients undergoing an 
angiography (n = 5809) at Helsinki University Central Hospital (HUS) were 
assessed for inclusion in the Genetic Predisposition of Coronary Artery 
Disease (COROGENE) study protocol. After exclusions due to a low 
haemoglobin or recent blood transfusion, prior heart transplant, non-Finnish 
citizenship or recurrent angiography for patients already in the cohort, 5294 
patients (91.1%) were ultimately included in the study. Amongst these, 2090 
(39.5%) patients were primarily diagnosed with ACS. The ACS diagnosis was 
based on an episode of typical chest pain associated with cardiac ischemia, an 
elevated biomarker measured from the patient’s blood sample (TnT and 
CKMBm at the time of cohort inclusion) and typical ischemic changes in ECG. 
Furthermore, to verify the diagnoses, at least one significant >50% stenotic 
lesion had to be identified in a coronary angiography. Studies I through IV of 
this thesis are based on this cohort of ACS patients from the COROGENE 
study. All patients were treated using the standard procedures and medical 
regimens characteristic for that time period. 
The COROGENE registry was collected from comprehensive medical 
records and from a two-page questionnaire patients completed during 
hospitalisation. The registry included information on the patient’s medical 
history, comorbidities, physical measurements such as height and weight, 
prior cardiovascular procedures, cardiovascular risk factors including 
smoking habits, information on the patient’s relatives, admission and 
discharge medications, angiography results, information on the 
revascularisation method (thrombolysis, PCI and CABG), laboratory samples, 
ECG findings and the patient’s current condition. 
All patients provided their written informed consent. The Ethics 
Committee of HUS approved the research protocol for the COROGENE study. 




In addition to the COROGENE registry, we merged different national datasets 
used in the studies at the patient level using each patient’s unique social 
security number. To assess drug usage and adherence to secondary prevention 
medications, information on filling prescriptions was collected from the Social 
Insurance Institution of Finland (SII). The Finnish Prescription Register from 
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the closed pharmacy system covers all prescription medication purchases, 
from which information beginning 1 January 2005 was acquired. For the 
statins in study I, medical follow-up lasted until March 2009. For the -
blocker and NSAID studies III and IV, data were updated to cover purchases 
until the end of the 2015. Data include information on filled prescriptions as 
follows: the date the prescription was filled, the anatomical therapeutic 
chemical (ATC) code of the drug, the strength of the medication (i.e., amount 
in grams or milligrams), the package tablet count and the number of packages 
reclaimed. Unfortunately, neither the indication for use nor the dosage 
prescribed was provided. 
To investigate the incidence of comorbidities, such as heart failure and 
cancer as well as the recurrence of cardiac events and other rehospitalisations, 
data on hospital discharge diagnoses and readmissions were aquired from the 
Finnish Institute for Health and Welfare. The Care Register for Health Care 
(HILMO) includes information on admission and discharge dates as well as 
the primary and secondary diagnoses for every hospitalisation in Finland. The 
follow-up period for these data began in January 2006 for studies II through 
IV and extended until December 2014 and December 2015, respectively, for 
studies II and studies III and IV. 
Information on causes of death and mortality were obtained from Statistics 
Finland, and follow-up lasted until the patient’s death or the end of the follow-
up period, whichever occurred first. The follow-up period lasted until 31 
March 2009 in study I and 31 December 2015 for studies II through IV. 
To analyse the number, frequency and type of blood transfusions given 
during the acute treatment of ACS patients, data on transfusions and 
haemoglobin values were obtained from the comprehensive hospital 
transfusion registry of HUS. These data consisted of information on the type 
and units of blood product(s) administered, the transfusion date and all 
measured haemoglobin values in HUS laboratories during the assessment 
period. Data covered all transfusions administered from January 2005 until 
October 2014. 
 
4.3 PATIENT SELECTION AND DEFINITIONS 
Table 2 summaries patient selection, exclusion criteria and final study 
populations, along with further details such as the follow-up periods and 
outcomes.  
4.3.1 ADHERENCE TO STATINS (STUDY I) 
In this study, all statin agents (ATC codes C10AA) were analysed as a single 
pooled-medication group. The methods to assess adherence to statins relied 
on the timing of the first refill following discharge, the number of refills and 
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the time intervals between them. In Finland, patients are reimbursed for 
prescription refills extending beyond a maximum of 3 months or 100 days. 
We assessed both primary and secondary adherence to statins following an 
ACS event. For secondary adherence, we divided patients into three statin user 
groups: regular users, irregular users and nonusers. If no prescriptions were 
filled during follow-up or after only one was filled more than 180 days until a 
patient’s death or until the end of the follow-up period, the patient was 
categorised as a nonuser. Patients who filled a prescription within 30 days 
after discharge followed by at least one refill with no intervals greater than 180 
days between refills were categorised as regular users. If neither of the 
aforementioned criteria were satified, the patient was categorised as an 
irregular statin user. To ensure that the results were not sensitive to our use of 
180 days as the cut-off for a permitted interval, we performed sensitivity 
analyses with refill intervals of 90, 120 and 150 days. To assess the utilisation 
of statins further, we examined the overall duration of statin use by calculating 
the time from the first to the last refill and adding 90 days to that time (50% 
of the assumed refill period). The overall duration was then divided by the total 
number of refills to calculate the mean interval between them. Regular statin 
users were further subdivided into groups based on the mean refill intervals of 
100 days or less versus more than 100 days, derived from the maximum 
reimbursement time (3 months) for a single refill in Finland. 
Primary adherence refers to how well patients adhere to the initiation of a 
new medication. Therefore, for these analyses, we excluded patients already 
taking statins prior to hospitalisation (n = 780). In total, we examined 1099 
statin-naïve patients, dividing them into three categories based on the timing 
of their first prescription fill following discharge: within 7 days, 7 to 120 days, 
after 120 days or no filling at all. 
 
4.3.2 RBC TRANSFUSION (STUDY II) 
In this substudy, 85 previously transfusion-naïve non-CABG patients treated 
with at least 1 RBC transfusion unit during hospitalisation were compared to 
1278 nontransfused patients. Due to the substantial discrepancy in both the 
size and characteristics of these two groups, we calculated the propensity score 
for RBC transfusion treatment using logistic regression. In the regression 
analyses, we included all baseline variables with a significant difference 
between groups applying p < 0.05. Using the propensity score, we then 
matched in a 1:1 fashion 65 patients to each group to mitigate any confounding 
from the significant differences between them. We assessed the adequacy of 
matching using c-statistics and the covariate balance applying the Hosmer–
Lemeshow goodness-of-fit test. The propensity score itself was eventually 
included as a covariate in the final multivariable models. To further verify 
findings adjusting for confounding and inflating the cohort size, we further 
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performed inverse propability treatment weighted (IPTW) Cox regression 
analyses after propensity matching. 
We obtained patients’ haemoglobin values from HUS laboratories and 
evaluated them at different time points during hospitalisation and follow-up. 
Hb levels were compared between transfused and nontransfused patients. Due 
to the strong correlations between nadir–Hb levels under 100g/l (Cramer’s V: 
0.789, p < 0.001) and 80g/l (Cramer’s V: 0.447, p < 0.001) and RBC treatment 
during hospitalisation, we could not include nadir–Hb in the multivariable 
models. However, to address any confounding from low haemoglobin levels, 
anaemia (based on the WHO definition described above) at baseline was used 
as a suitable candidate confounder in both the logistic regression for the 
propensity scoring as well as in the final multivariable models. In addition, 
RBC-transfused patients with a nadir–Hb over 80g/l were compared to 
patients with a nadir–Hb below 80g/l. Furthermore, subgroup analyses of 
anaemic and nonanaemic patients were performed to determine what more 
prominently influenced mortality between RBC transfusion and anaemia. 
 
4.3.3 ADHERENCE TO -BLOCKERS (STUDY III) 
In study III, we assessed the utilisation of prescribed [excluding over-the-
counter (OTC) aspirin] secondary prevention medications in pooled 
pharmacological groups. Pooled groups were formed using the anatomical 
therapeutic chemical (ATC) codes; -blockers (ATC: C07), statins (ATC: 
C10AA and C10BA) and renin-angiotensin-aldosteron (RAA) inhibitors 
consisting of angiotensin-converting enzyme (ACE) inhibitors together with 
angiotensin receptor blockers (ARB) (ATC: C09). The preferred ADP inhibitor 
by the time of our cohort recruit, clopidogrel, was pooled with newer 
antiplatelet medications (ATC: B01AC04–05, 07, 22, 24 and 30) and their 
usage was examined only for the first 12 months following discharge. 
Adherence to each pooled medication group was assessed on an annual 
basis separately and the adherence status of each year was then introduced to 
the survival analyses as a time-dependent variable. To define annual 
adherence, the follow-up time was split into periods of 365 days, beginning 
from the discharge date and ending at patient’s death or at the end of the 
follow-up period. A specific yearly period was categorised as adherent if the 
patient filled the presctiption ≥3 times during the year and 180 days or more 
elapsed from the first through the last refill. In previous studies, this method 
was associated with an 80% adherence rate, typically the cut-off for good 
adherence.354,355 For a death during the assessment period, the patient was 
also considered adherent if one of the following conditions was satisifed:  
 
1. The patient filled 1 to 2 presciptions during the period and the time 




2. The patient recorded zero refills during the period, although the 
preceding period featured adherence and the interval between the 
last refill and both the beginning of the next period and the patient’s 
death did not exceed 100 days.  
 
If neither of these criteria were met, the yearly period was defined as 
nonadherent. The 100-day interval stems from the maximum reimbursement 
time for Finnish pharmaceuticals. As sensitivity measures, we also assessed 
intervals of 90 and 120 days. Furthermore, for sensitivity, adherence was also 
examined as a three-category variable based on the number of annual refills: 
poor (0–1 refills), intermediate (2 refills) and good (3 or more refills). 
This study focused on -blockers, such that the usage of other drugs was 
primarily assessed as a confounding factor. However, adherence to each of the 
secondary prevention medications was assessed separately. Furthermore, the 
association between survival and adherence to each medication was examined 
in univariable models by excluding patients without a prescription to the drug 
in question. 
In the multivariable models, however, only the effect of adherence 
specifically to -blockers on survival was analysed, whilst adjusting for the 
concomitant usage of other drugs. Hence, only patients prescribed -blockers 
upon discharge were included in these multivariable analyses. Adherence and 
its effect on survival was also examined in low-risk and high-risk patient 
subgroups.356,357 A patient was regarded as high risk if they suffered a prior 
MI, was diagnosed with HF (HILMO) at baseline or was diagnosed with triple 
vessel disease in CAG. Otherwise, patients were considered low risk. 
4.3.4 NSAID USE 
In contrast to secondary prevention medications, ACS patients should avoid 
using NSAIDs. Therefore, methods to examine the utilisation of these drugs 
also differed from previous studies. To estimate changes in prescribed NSAID-
use behaviour across years, follow-up was again divided into yearly periods 
and the number of NSAID prescription fills for each annual period was 
determined. For the utilisation analyses, we identified the number and 
percentage of patients filling at least one or at least three NSAID prescriptions 
per year. We then assessed these annual utilisation rates throughout the 
follow-up period. 
Prior studies found that the adverse effects of NSAIDs may both appear and 
vanish quite rapidly after the initiation and discontinuation, respectively, of 
administering a medication.47,285,358 To assess the association of recent or 
current NSAID use with patient death or recurrent MI, we identified the 
nearest NSAID refill before an outcome event. The days’ supply for this refill 
was estimated using information on the tablet count from a purchase (SII 
registry) combined with a defined daily dose (DDD) provided by WHO for each 
medical agent.359 Patients were then categorised as current NSAID users and 
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nonusers for a comparison. If the days’ supply of the most-recent refill lasted 
at least until 30 days before the event, the patient was defined as a current 
user. If there were no NSAID prescription fills or the days’ supply ended more 
than 30 days before the outcome, the patient was considered a nonuser. For 
the sensitivity measures, user definitions based on half the DDD as well as a 
doubled DDD were also examined. Furthermore, we also assessed usage 
defined in the same manner using a 60-days cutoff for the days’ supply before 
the event. 
The concomitant use of secondary prevention medications was adjusted by 
assessing their usage in a similar days’ supply method based on DDDs and 
tablet counts. The medication groups formed using the ATC codes were 
identical to study III. Using different NSAID agents, their proportional usage 
was calculated; yet, given the low number of NSAID refills, all NSAID agents 
were assessed as one pooled medication group (ATC: M01A). 
To further investigate NSAID usage and its effect on ACS patient prognosis, 
we divided the study population into high- and low-risk patient subgroups, 
defined in manner similar to that in study III. 
 
 
4.4 STATISTICAL METHODS 
All statistical analyses were performed using IBM’s SPSS software, versions 
from 18.0 to 24.0 (SPSS, Inc., Chicago, IL, USA). We considered p < 0.05 as 
statistically significance using two-tailed tests. Across all studies, we compared 
baseline characteristics and other variables between defined groups. We used 
cross-tabulations to analyse categorical variables and the differences were 
tested using either chi-square or the Fisher’s exact test, whichever was 
appropriate for the specific variable. Values are stated as percentages, with 
continuous variables presented as either a median with an interquartile range 
(IQR) or a mean with the standard deviation (SD) depending upon the 
suitability. We assessed the normality of distribution for continuous variables 
graphically and using the Kolmogorov–Smirnov test. If normally distributed, 
we analysed continuous variables using an independent samples t-test; 
nonparametric tests, namely, the Mann–Whitney U, were applied to 
nonnormally distributed variables.  
In studies I through III, univariable comparisons of the mean survival 
times for each variable were analysed using the Kaplan–Meier survival 
analysis, whereby the associations for each candidate confounding variable 
and its impact on survival was also assessed using a univariable Cox 
proportional hazards model. For these, hazard ratios (HRs) with 95% 
confidence intervals (CIs) are presented. The final multivariable Cox 
proportional hazards models were constructed from candidate variables based 
Methods 
46 
on their clinical relevance from prior studies as well as based on their 
statistical significance on outcomes in univariable models. 
 
In studies I and II, variables were entered into the Cox regression models 
with both forward and backward stepwise variable-reduction methods to form 
the final equations. In studies III and IV, the introduction of covariates to the 
multivariable models were carried out using the enter method. For the Cox 
regression models, the assumption regarding proportional hazards was tested 
through a visual comparison of the Kaplan–Meier curves as well as by plotting 
the Schoenfeld’s residuals against survival time. We observed no violations. 
The multicollinearity, in turn, was examined using variation inflation factors 
(VIFs) between independent variables. No deviations with a value >2.5, 
considered the significant threshold of collinearity, were observed. In study 
III, the incidence of HF during the follow-up, usage of other secondary 
prevention medications and adherence to -blockers were analysed as time-
dependent variables in the Cox proportional hazards models. HRs with 95% 
CIs are reported. In study II, in addition to the regular Cox regressions models 
before and after matching, an IPTW Cox proportional hazards model was also 
calculated following propensity score matching. 
In study IV, given the nature of the method used to assess current NSAID 
use, logistic regression was utilised to both examine the effect of each 
candidate variable on the composite endpoint of mortality and recurrent MI 
in univariable models as well as to calculate the final multivariable models. 
Results are reported in odds ratios (ORs) with the corresponding 95% CIs. A 
VIF value of 2.5 was again considered the significant thresfold for 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.1 CHARACTERISTICS OF THE STUDY COHORT 
The final cohorts in studies I through IV differed slightly from each other due 
to the exclusion criteria mentioned previously. A comparison in the general 
characteristics of patients from the specific substudy groups can be found in 
the attached original publications for studies I through III, and in the 
manuscript for study IV. Table 3, however, summarises these characteristics 
amongst both deceased and surviving patients from study III 
Table 3. Characteristics of surviving and deceased patients in study III. 
Abbreviations: ACE, angiotensin-converting enzyme; ACS, acute coronary 
syndrome; eGFR, estimated glomerular filtration; HILMO, Care Register for 
Health Care; IQR, interquartile range; SD, standard deviation. Adapted from 
Allonen et al. (2020), reprinted with permission from Taylor & Francis Group.360  
 Survivors 
(n = 1297) 
Deceased 
(n = 558) 
p value 
Demographic characteristics    
Age in years, median (IQR) 62.6 (16.0) 74.4 (14.5) <0.001  
Age >65 years, % 43.3 79.4 <0.001 
Female, % 26.6 37.8 <0.001 
Body mass index, kg/m², mean ± SD 26.9 (±5.4) 26.3 (±5.0) 0.003 
Smoker/ex-smoker, % 65.7 60.7 0.041 
Comorbidities, %   
 
Diabetes 18.8 33.5 <0.001 
Hypertension 62.4 72.8 <0.001 
Kidney disease 1.0 5.4 <0.001 
eGFR >60 ml/min/1.73 m², % 91.3 69.9 <0.001 
Peripheral artery disease 6.5 16.5 <0.001 
Atrial fibrillation 5.0 19.5 <0.001 
Cerebrovascular disease 9.3 17.5 <0.001 
Prior myocardial infarction 15.4 33.3 <0.001 
Cardiac insufficiency at baseline (HILMO) 4.3 22.8 <0.001 
Baseline anaemia 23.5 48.9 <0.001 
Malignancy 5.8 12.9 <0.001 
Prior procedures, %   
 
Coronary artery bypass graft surgery 7.2 16.1 <0.001 




(n = 1297) 
Deceased 
(n = 558) 
p value 
Vascular operation: lower extremity 2.0 6.7 <0.001 
Characteristics of ACS, %   
 
Triple vessel disease 18.7 40.0 <0.001 
Unstable angina pectoris 11.5 10.0 0.360 
Non-ST-elevation myocardial infarction 50.5 63.6 <0.001 
ST-elevation myocardial infarction 38.0 26.3 <0.001 
Procedures, %   
 
Percutaneous coronary intervention 77.5 61.5 <0.001 
Coronary artery bypass graft surgery 13.4 17.9 0.012 
Thrombolysis 13.7 5.9 <0.001  
Red blood cell transfusion during hospitalisation 13.0 22.6 <0.001 
Discharge medications, %   
 
β-blocker 91.6 91.0 0.682 
Statin 97.2 91.2 <0.001 
Clopidogrel 84.0 70.3 <0.001 
ACE inhibitor 59.4 54.6 0.054 
Angiotensin receptor blocker 14.7 16.4 0.336 
Acetylsalicylic acid 94.2 88.4 <0.001 
Calcium channel blocker 9.7 20.0 <0.001 
Digoxin 0.9 5.8 <0.001 
Diuretic 17.9 45.1 <0.001 
Nitrate 13.0 32.1 <0.001 
Warfarin 3.7 14.8 <0.001 
Low molecular weight heparin 12.5 23.0 <0.001 
Insulin 6.8 15.7 <0.001 
Oral diabetic medications 10.4 16.0 0.001 
Nonsteroidal antiinflammatory drugs 6.9 13.2 <0.001 
Adherence to medications, 1st year, %    
β-blocker 88.7 82.4 <0.001 
Statins 88.4 80.4 <0.001 
ACE inhibitor / angiotensin receptor blocker 89.8 79.8 <0.001 
Clopidogrel 85.6 71.9 <0.001 
Adherence to medications, 8th year, %    
β-blocker 73.0 52.7 <0.001 
Statins 67.6 43.0 <0.001 
ACE inhibitor / angiotensin receptor blocker 74.0 47.4 <0.001 
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5.2 UTILISATION OF MEDICATIONS  
5.2.1 ADHERENCE TO STATINS (STUDY I) 
In study I, a statin was prescribed to 95% (n = 1878/1969) of discharged 
patients and 90.5% (n = 1761/1945) of patients still living one month after 
initiating or continuing their statin therapy. In total, 58.5% (n = 1099/1969) 
were statin-naïve upon discharge, amongst whom 79.9% (n = 878) filled the 
prescription within 7 days following discharge and with another 13.1% (n = 
144) did so within 7 to 120 days. A total of 77 (7.0%) patients did not fill the 
statin prescription at all and were, thus, primarily nonadherent. Those who 
filled the prescription within one week were eventually more likely to be 
regular statin users and less likely to be irregular statin users than those who 
filled the prescription within the first 4 months (regular users: 76.5% vs. 
49.3%, p < 0.001 and irregular users: 21.5% vs. 49.3%, p < 0.001, respectively). 
We also found that 62.0% (n = 1205) and 59.4% (n = 1155) regularly used 
a statin without a single refill interval of more than 180 days at the 1- and 2-
year time points following discharge. Using the definition outlined previously, 
61.7% (n = 1200/1945) of patients were identified as regular statin users 
throughout their follow-up, whilst 33.5% (n = 651/1945) and 4.8% (n = 
94/1945) were irregular users and nonusers, respectively. Amongt 86.3% (n = 
1036/1200) of the regular users, the mean time interval between refills was 
100 days or less, whilst 13.7% (n = 164) requested fills after more than 100 
days. In the sensitivity analysis for statin use, only 1.7% (n = 33), 32.2% (n = 
627) and 51.6% (n = 1004) were defined as regular users using a cut-off for the 
interval of 90, 120 or 150 days, respectively. 
 
5.2.2 ADHERENCE TO -BLOCKERS (STUDY III) 
In study III, adherence to secondary prevention medications was assessed 
separately for each year following discharge. We found that 91% (n = 1693) of 
patients who were still living 30 days following angiography were prescribed 
-blockers upon discharge. Respectively, 95% (n = 1770), 72% (n = 1335) and 
80% (n = 1480) were prescribed statins, RAA inhibitors and clopidogrel. The 
adherence rates to these medications for the first year were 86.8% (n = 
1470/1693) for -blockers, 86.1% (n = 1524/1770) for statins, 86.9% (n = 
1160/1335) for RAA inhibitors and 82.0% (n = 1215/1480) for clopidogrel. The 
adherence rates decreased each year as time passed from the ACS event, and 
for -blockers diminished to 71.3% (n = 926/1299) by the eighth year of follow-
up, to 72.0% (n = 739/1027) for RAA inhibitors and to as low as 65.5% (n = 
901/1375) for statins.  
Results 
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5.2.3 NSAID USE (STUDY IV) 
17.7% of patients filled at least one NSAID prescription during the first year 
following discharge. A peak in yearly NSAID utilisation was observed during 
the second year of follow-up, after which the utilisation rate slightly decreased 




Figure 3 Annual NSAID usage rates during follow-up. 
As many as 54.3% (n = 1042/1919) of patients filled at least one NSAID 
prescription during the entire follow-up period. Furthermore, 14.5% (n = 
278/1919) of patients filled 3 or more NSAID prescriptions during at least one 
of the yearly time periods during follow-up. However, ultimately only 88 
(4.6%) patients were defined as current NSAID users before the outcome 
event. The mean days’ supply remaining at the event was 18.8 days (SD  36.9 
days). Ibuprofen was the most common NSAID agent used amongst current 
users (Figure 4). Current NSAID users were compared to nonusers, and were 
more often treated with PCI, less frequently with CABG and did not have HF 
and anaemia at baseline as often as nonusers. Otherwise, the groups were 






Figure 4 The proportion of different NSAID agents amongst current users’ last filled 
prescriptions. 
5.3 THE EFFECT OF MEDICATION USE ON PROGNOSIS  
Although not entirely comparable given the different methods used in the 
substudies, the final multivariable risk ratios for the corresponding primary 
outcome for each of the primary medication groups we examined appear in 
Table 4.  
 
Table 4. Adjusted multivariable risk ratios for the primary outcomes in studies I, III 
and IV. Abbreviations: CI, confidence interval; HR, hazard ratio; NA, 
nonadherence; OR, odds ratio; TD, time dependent. 
 
NA to statins 
(study I) 
NA to -blockers 
(study III) 
Current NSAID use 
(study IV) 
Regression Cox regression TD Cox regression Logistic regression 
Outcome Mortality Mortality Mortality + Recurrent MI 
HR / OR 
2.70 
(95% CI 1.49–4.90) 
 p = 0.001 
1.84 
(95% CI 1.51–2.24) 
p < 0.001 
1.75 
(95% CI 1.10–2.78) 




























5.3.1 STATINS (STUDY I) 
The most strictly adherent patients primarily refilling the statin prescription 
within 7 days following hospitalisation exhibited a markedly lower all-cause 
mortality compared with patients refilling the prescription within the first 120 
days (3.2% vs. 10.4%, p < 0.001). Less consistent primary adherence was 
associated with an increased relative risk of mortality in an adjusted Cox 
proportional hazards model [HR 2.34 (95%CI 1.19–4.59), p = 0.013].  
Furthermore, the better the secondary adherence to statins, the lower the 
all-cause mortality [4.9% for regular users, 9.4% for irregular users and 14.9% 
for nonusers (p < 0.001)] as well as for CV mortality (2.9%, 5.1% and 7.4%, 
respectively, p = 0.013). We identified a stepwise increase in mortality by 
adherence status in a multivariable Cox model adjusted for age, ACS type, 
triple vessel disease, DM, cerebrovascular disease and a previous malignancy 
[irregular users: HR 1.53 (95%CI 1.06–2.21), p = 0.023; nonusers: HR 2.70 
(95%CI 1.49–4.90), p = 0.001) compared to regular users]. In addition, 
amongst regular statin users, a mean interval between refills of more than 100 
days also associated with a higher mortality compared to those regular statin  
users with a mean interval of fewer than 100 days [11.0% vs. 4.0%, p < 0.001] 
with an adjusted HR of 2.34 (95%CI 1.33–4.12, p = 0.003). 
 
 
Figure 5 Univariable Kaplan–Meier proportional propability of survival curves for 
secondary adherence to statins. Adapted from Allonen et al. (2012), reprinted 
with permission from John Wiley & Sons.361 
 
55 
In the sensitivity analyses, the effect was otherwise similar, although with a 
90-day interval, we observed no significant difference in mortality due to the 
low number of regular users. Absolute mortality was significantly lower 
amongst regular users with no intervals greater than 120 (3.7%, p < 0.001) and 
150 days (3.9%, p < 0.001) compared to nonusers (14.9%). 
5.3.2 -BLOCKERS (STUDY III) 
We investigated the survival benefit from adherence to each of the secondary 
prevention medications separately in a univariable Cox proportional hazards 
models for both primary and secondary outcomes. Table 5 presents the hazard 
ratios for these analyses. Since clopidogrel is usually prescribed only for the 
first year following an ACS event, we assessed it as a non-time-dependent 
variable in survival analyses. In a multivariable confounder-adjusted survival 
analysis, we found that nonadherence to -blockers associated with an 
increased risk of all-cause mortality in terms of overall survival (OS) [HR 1.84 
(95% CI 1.51–2.24, p < 0.001] and on 1-year landmark survival (1YLS) [HR 
1.74 (95% CI 1.41–2.14, p < 0.001]. Likewise, the risk of coronary mortality 
also increased with nonadherence to -blockers [OS: HR 1.67 (95% CI 1.24–
2.26, p = 0.001; 1YLS: HR 1.55 (95% CI 1.12–2.14, p = 0.008; see Table 7). In 
a sensitivity analysis, using adherence as a three-category variable ranging 
from good, intermediate and poor, the stepwise increase in HR for both all-
cause and coronary mortalities remained relativley consistent. Yet, in the 1YLS 
analysis, the impact of intermediate adherence on coronary mortality was 
barely statistically nonsignificant. Table 6 summarises the results of the 
sensitivity analyses.  
Table 5. Univariable analyses for each secondary prevention medication. 
Abbreviations: 1YLS, one-year landmark survival; CI, confidence interval; OS, 
overall survival.  
 ALL-CAUSE MORTALITY CORONARY MORTALITY 
 OS 1YLS OS 1YLS 
-blockers 2.99 
(95% CI 2.50–3.57) 
2.71 
(95% CI 2.25–3.27) 
2.62 
(95% CI 2.01–3.42) 
2.23 
(95% CI 1.67–2.97) 
Statins 3.49 
(95% CI 2.91–4.17) 
3.20 
(95% CI 2.64–3.87) 
2.83 
(95% CI 2.17–3.68) 
2.34 




(95% CI 3.31–4.98) 
4.02 
(95% CI 3.23–4.99) 
4.11 
(95% CI 3.06–5.53) 
4.01 
(95% CI 2.92–5.53) 
Clopidogrel 2.09 
(95% CI 1.68–2.61) 
1.89 
(95% CI 1.49–2.41) 
2.34 
(95% CI 1.69–3.25) 
2.04 




In addition to mortality, we also assessed the effect of adherence on 
rehospitalisations for different reasons during the entire follow-up period. In 
the univariable Cox regressions, nonadherence to -blockers increased the risk 
of rehospitalisations for recurrent MI; HR 1.39 (95% CI 1.05–1.82, p = 0.020); 
for HF; HR 1.61 (95% CI 1.27–2.03), p < 0.001; for CV diagnoses: HR 1.54 
(95% CI 1.27–1.88), p < 0.001 and for non-CV diagnoses; HR 1.16 (95% CI 
1.02–1.31), p = 0.019. However, in multivariable models, only 
rehospitalisations for HF and CV diagnoses were associated with 
nonadherence to -blockers [HR 1.57 (95% CI 1.23–2.02), p < 0.001 and HR 
1.30 (95% CI 1.05–1.62), p = 0.016, respectively]. HRs for recurrent MI and 
non-CV diagnoses were 1.16 (95% CI 0.86–1.56, p = 0.332) and 1.10 (95% CI 
0.96–1.25, p = 0.179), respectively. 
Table 6. Multivariable sensitivity analyses for nonadherence to -blockers.  
 Hazard ratios with 95% confidence intervals are presented. Adapted from 
Allonen et al. (2020) reprinted with permission from Taylor & Francis Group.360 
 ALL-CAUSE MORTALITY CORONARY MORTALITY 
 Overall survival 1-year landmark Overall survival 1-year landmark 
 Sensitivity analysis, graded adherence 
Good Reference Reference Reference Reference 
Intermediate 1.53 
(95% CI 1.17–2.00) 
1.41 
(95% CI 1.06–1.89) 
1.60 
(95% CI 1.08–2.36) 
1.49 
(95% CI 0.97–2.29) 
Poor 2.55 
(95% CI 2.03–3.20) 
2.37 
(95% CI 1.87–3.02) 
2.30 
(95% CI 1.61–3.27) 
2.12 
(95% CI 1.45–3.09) 
 Sensitivity analysis, 90-day interval 
Nonadherent 2.40 
 (95% CI 1.96–2.93) 
2.24 
 (95% CI 1.81–2.77) 
2.22  
(95% CI 1.64–3.00) 
1.98  
(95% CI 1.44–2.74) 
 Sensitivity analysis, 120-day interval 
Nonadherent 1.49  
(95% CI 1.22–1.82) 
1.40  
(95% CI 1.14–1.73) 
1.30  
(95% CI 0.96–1.77) 
1.23 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.3 NSAIDS (STUDY IV) 
During follow-up, 48.7% (n = 935) of those patients still living 30 days 
following CAG suffered the composite endpoint of a recurrent MI or death. 
Amongst these, 29.7% (n = 570/1919) experienced a recurrent MI as the end 
event during follow-up, whilst 19.0% (n = 365/1919) of patients died. The 
mean survival time until the end event was 6.2 years (SD  3.2 years). 
Recurrent MI occurred sooner on average than death [3.1 years (SD  2.5 
years) and 4.1 years (SD   2.8 years), respectively]. 
We observed no significant difference in the incidence in the composite 
outcome when we compared current NSAID users to nonusers in absolute 
figures [53.4% (n = 47) vs. 48.5% (n = 888)] or in a univariable logistic 
regression [OR 1.22 (95% CI 0.79–1.87), p = 0.369]. In a multivariable 
adjusted logistic regression, however, current NSAID use associated with a 
increase in the risk of recurrent MI and death [OR 1.75 (95% CI 1.10–2.78), p 
= 0.019; Figure 6). 
 
Figure 6 Multivariable predictors of the composite endpoint in a logistic regression 
model. 
In the sensitivity analyses, 71 (3.7%), 124 (6.5%) and 120 (6.3%) patients were 
defined as current users, using twice the DDD, half the DDD and a days’ supply 
end cut-off of 60 days to categorise groups, respectively. As in the primary 
analyses, we found no significant impact on survival in univariable analyses 
with the sensitivity definitions either. However, in multivariable logistic 
regressions using half the DDD definition and ‘60- days’ definition, NSAID use 
increased the risk of outcomes [OR 1.53 (95% CI 1.03–2.28), p = 0.036 and 
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OR 1.62 (95% CI 1.08–2.43), p = 0.019]. OR for twice the DDD definition was 
1.60 (95% CI 0.96–2.69, p=0.073). 
 
5.3.4 LOW- AND HIGH-RISK PATIENTS 
In studies III and IV, we further analysed the effects of -blockers and NSAIDs, 
respectively, amongst subgroups of low- and high-risk patients. In study III 
amongst high-risk patients, nonadherence to -blockers associated with an 
increased risk of both all-cause mortality and coronary mortality in OS and 
1YLS. In addition, an increased risk for readmission due to HF although not 
for other reasons also associated with nonadherence to -blockers amongst 
both risk groups [ for high-risk patients: HR 1.62 (95% CI 1.06–2.49), p = 
0.026; and for low-risk patients: HR 1.60 (95% CI 1.18–2.18), p = 0.003]. Yet, 
amongst low-risk patients, both OS and 1YLS, only an increased risk of all-
cause mortality but not coronary mortality accompanied nonadherence to β-
blockers. Table 8 summaries the HRs for nonadherence to -blockers 
calculated from the multivariable models within each risk group. 
 
Table 8. Nondherence to -blockers amongst low- and high-risk patients. Hazard 
ratios with 95% confidence intervals in multivariable survival analyses for 
primary and secondary outcomes based on overall survival and one-year 
landmark survival analyses. 
 ALL-CAUSE MORTALITY CORONARY MORTALITY 








(95% CI 1.58–2.61) 
1.92  
(95% CI 1.47–2.51) 
1.84  
(95% CI 1.29–2.62) 
1.67  
(95% CI 1.14–2.45) 
Low risk 
1.60 
(95% CI 1.16–2.21) 
1.57  
(95% CI 1.12–2.20) 
1.37  
(95% CI 0.77–2.45) 
1.32  
(95% CI 0.71–2.46) 
 
 
The trends in use of prescribed NSAIDs following ACS in study IV mirrored 
the main cohort in both risk groups. At least one prescription per year was 
filled in the first year by 18.4% (n = 207) of low-risk and 16.7% (n = 133) of 
high-risk patients, by 24.4% (n = 269) and 18.5% (n = 136) in the second year 
and by 16.7% (n = 163) and 10.0% (n = 50) of low- and high-risk patients, 
respectively, in the eighth year. In total, 62 (5.5%) patients were defined as 
current NSAID users within the low-risk group, amongst whom NSAID use 
was associated with an increased risk for recurrent MI and death in 
multivariable logistic regression analysis [OR 2.03 (95% CI 1.19–3.48), p = 
Results 
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0.010]. Amongst high-risk patients, current NSAID use (n = 26, 3.3%), 
however, did not significantly affect survival [OR 1.19 (95% CI 0.50–2.85), p 
= 0.697]. 
 
5.4 RED BLOOD CELL TRANSFUSIONS (STUDY II) 
A total of 85 previously transfusion-naïve, non-CABG patients who survived 
at least 30 days following CAG received at least one RBC transfusion during 
the index hospitalisation. Overall, they received a median of 8 (IQR 2–9) 
international units (IU) of packed RBCs cumulatively, the first of which was 
transfused at a mean of 5.6 (SD ± 6.3) and 4.2 (SD ± 6.2) days following 
admission and CAG, respectively. Table 9 summaries the primary indications 
for transfusion. RBC-transfused patients, in general, were older and sicker 
than those who did not receive any transfusions (n = 1278). They more often 
presented with hypertension, DM, FA, CKD, a prior cancer, more severe CAD 
and were more often anaemic females. Other than the Hb values, no significant 
differences were observed following 1:1 propensity-score matching. The 
propensity matching achieved both a good statistical discrimination and 
adequate covariate balance [C-statistic: 0.91, (95%CI 0.88–0.94) and 
Hosmer–Lemeshow, chi-square 3.64, p = 0.888]. 
 
Table 9. Primary indications for red blood cell transfusion. Abbreviation: LAD, left-
anterior descending coronary artery. Adapted from Allonen et al. (2018) 
reprinted with permission from Elsevier.362 
Primary indications for transfusion n % 
Not available 36 42.4 % 
Coronary angiography access site (femoral) hemorrhage 26 30.6 % 
Gastrointestinal bleeding 7 8.2 % 
Perioperative transfusion (related to, i.e., a vascular procedure) 5 5.9 % 
Chronic anaemia 4 4.7 % 
Retroperitoneal haematoma 2 2.4 % 
Haematuria 2 2.4 % 
Peritoneal bleeding 1 1.2 % 
Cancer related 1 1.2 % 
Procedure complication (LAD rupture) 1 1.2 % 






5.4.1 THE EFFECT OF RBC TRANSFUSION ON LONG-TERM 
MORTALITY 
Before matching, overall mortality amongst patients treated with RBC 
transfusion was almost threefold higher compared to nontransfused patients 
[58.8% (n = 50/85) vs. 20.3% (n = 259/1278), p < 0.001]. The absolute 
mortality figures after propensity matching remained twice as high amongst 
RBC- transfused patients [52% (n = 34/65) vs. 34% (n = 22/65), p = 0.034]. 
The mean survival times before and after matching revealed similar results as 
well; 5.9 years (95% CI 5.2–6.7) for RBC patients and 8.5 years (95% CI 8.4–
8.6, p < 0.001) for nontransfused patients before matching and 6.3 years (95% 
CI 5.5–7.1) for RBC patients and 7.6 years (95% CI 6.9–8.3, p = 0.035) for 
nontransfused patients after matching (Figure 7). 
In a multivariable Cox proportional hazards model amongst an 
unmatched cohort, RBC transfusion associated with a twofold higher risk of 
death [HR 1.91 (95% CI 1.39–2.63), p < 0.001]. This finding persisted in the 
1YLS analysis. Furthermore, after matching with the propensity score itself 
included as a covariate in the model, RBC transfusion remained independently 
associated with higher mortality in terms of both OS and 1YLS (Table 11). In 
an IPTW Cox regression model, yet again, we found an almost twofold increase 
in the risk of death in both OS [weighted n = 2130.6; HR 1.70 (95% CI 1.11–
2.59), p = 0.015] and in 1YLS [weighted n = 2012.0; HR 2.07 (95% CI 1.38–


















































































































































5.4.2 HAEMOGLOBIN LEVELS AND ANAEMIA 
In general, anaemic patients exhibited a greater absolute mortality in the 
unmatched cohort when compared to their nonanaemic counterparts [45.8% 
(n = 215/469) vs. 21.4% (n = 239/1116), respectively]. Furthermore, patients 
with their lowest Hb value during a hospital stay, which fell below 100g/l, 
increased the risk of mortality compared to those with an Hb level ≥100 g/l 
[56.1% (n = 97/173) vs. 25.1% (n = 341/1360), p < 0.001, respectively]. The 
differencies in the Hb levels measured during hospitalisation and later during 
follow-up between RBC-transfused and nontransfused patients appear in 




Figure 8 Mean haemoglobin values amongst both nontransfused and RBC-transfused 
patients at different timepoints during the course of treatment. Abbreviations: 
RBC, red blood cell. Adapted from Allonen et al. (2018), reprinted with permission 
from Elsevier.362 
The nadir–Hb in RBC-transfused patients, in turn, fell below 100g/l in 98.8% 
(n = 84/85) and under 80g/l in 22.4% (n = 19/85) of patients. Amongst RBC-
transfused patients, we detected no difference in the mortality figures between 
patients with nadir–Hb less than or more than 80g/l [57.9% (n = 11/19) vs. 
59.1% (n = 39/66), p = 0.926, respectively]. Furthermore, in the multivariable 
subgroup analyses for both anaemic (n = 344) and nonanaemic (n = 951) 
patients, RBC transfusion associated with an increased risk of mortality in 




Table 10. The multivariable hazard ratios with 95% confidence intervals on 1-year 
landmark survival and overall survival for red blood cell transfusion in 
subgroups of anaemic and nonanaemic patients. Abbreviations: CI, 
confidence interval. 
 ALL-CAUSE MORTALITY 





(95% CI 1.05–2.29) 
1.63  
(95% CI 1.07–2.47) 
Nonanaemic  
3.57 
(95% CI 1.65–7.72) 
3.02  
(95% CI 1.22–7.48) 
 
5.4.3 ASSOCIATION WITH CANCER 
We further investigated mortality by analysing the causes of death. Cancer 
(ICD-10: C diagnoses) was surprisingly overrepresented within RBC-
transfused patients [15.3% (n = 13/85) vs. 4.1% (n = 52/1278), p < 0.001]. The 
incidence of new cancer diagnoses amongst transfused patients during follow-
up, however, did not differ from that amongst nontransfused patients [19.5% 
(n = 16/82) vs. 13.1% (n = 165/1262), p = 0.098, respectively]. Yet, RBC 
transfusion associated with an increased risk of cancer mortality in an age- 
and smoking-adjusted multivariable Cox regression model [HR 2.89 (95% CI 
1.44–5.77), p = 0.003]. For this analysis, we excluded patients diagnosed with 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study of consecutive ACS patients examined using CAG, we defined 
adherence rates to secondary prevention medications, specifically to statins 
and -blockers during an extensive follow-up period. Furthermore, we 
demonstrated the importance of patients’ strict medical behaviour even years 
after an ACS event enabling a better survival. This study also investigated if 
ACS patients continue using NSAIDs despite gradually tightened restrictions 
within guidelines. Additionally, we examined the effect of RBC transfusion on 
ACS patients’ long-term prognosis seeking to understanding the phenomena 
behind adverse events previously associated with them by examining the 
incidence of new cancer diagnoses and cancer mortality during follow-up. 
 
6.1 ADHERENCE TO STATINS 
All-cause mortality amongst ACS patients was profoundly associated with the 
level of adherence to statins in study I. The absolute mortality figures for 
nonadherent patients were threefold higher compared to those amongst 
regular statin users. These figures are markedly higher than in placebo-
controlled trials, although quite consistent with previous observational 
studies.151,198,215,363 The increase in the relative risk of death related to the 
nonuse of statins also remained consistent, although slightly greater compared 
to studies published both prior to and following our analysis.17,20,364,365 We 
observed a stepwise increase in mortality figures associated with the 
adherence level from regular to intermediate users to nonusers. Moreover, 
amongst regular statin users, patients with the most regimented refill 
behaviour exhibited the lowest risk for death. These results reflect both the 
importance of strictly continuous statin therapy following ACS, as well as the 
nature of adherence itself. Specifically, the healthy adherer bias possibly 
affected our results to some extent.  
Within our cohort, as many as 95% of discharged patients were prescribed 
statins. This demonstrates the close compliance with guidelines amongst 
physicians. In addition to long-term adherence, we assessed primary 
adherence to statins. Amongst patients with a new statin prescription upon 
discharge, about 80% filled it within the first week. This agrees with previous 
studies as well.17 Interestingly, primary adherence independently associated 
with both decreased long-term mortality, as well as with increased secondary 
adherence. Hence, it is of great importance to motivate patients to fill their 
prescriptions immediately following hospitalization. It seems that if attention 
is devoted to this moment, patients tend to adhere better to their secondary 
prevention therapies in long-term as well.17,214 For instance, nurse-based 
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reminder calls or appointments could result in greater medical compliance in 
future.226,227 
Secondary adherence to statins diminished drastically during follow-up. 
Whilst about 90% initiated or continued their statin therapy upon discharge, 
only slightly more than 60% of patients were considered regular statin users 
throughout a two-year follow-up. These figures are unfortunately quite similar 
to previous and more recent findings, whereby around 40% to 75% adherence 
rates emerged at 1- to 2-year landmarks.16,18,20,179,206,207,366-368 In the last 
decade, however, it seems that adherence to secondary prevention 
medications including statins has improved to a small degree.231,369,370 Still, 
when compared with the neglible 5-year discontinuation rates of 6% to 19% in 
landmark secondary prevention trials, these figures appear rather 
grim.198,363,371 Furthermore, in study III, which primarily assessed -blockers, 
we observed a decrease in yearly adherence rates to statins from nearly 90% 
during the first year to less than 70% by the eighth year of follow-up amongst 
surviving patients. Amongst deceased patients, statin adherence decreased 
even further, from 80% to as low as 43% during the same time frame. 
Naturally, these figures are not directly comparable to other studies given the 
varied methods used to estimate adherence rates. 
In conclusion, even in Finnish society with a population-wide medical care 
and reimbursement system, ACS patients’ adherence to statins remains 
unsatisfactory, and nonadherence is associated with a poorer prognosis. 
Measures should be taken to improve adherence, and attention should 
specifically focus on the moment of discharge and the first days following 
discharge to ensure the initiation of life-saving therapies.  
 
6.2 ADHERENCE TO β-BLOCKERS 
In our cohort, -blockers were prescribed to more than 90% of discharged 
patients. At the time of patient recruitment to this study, the European expert 
consensus document on -blockers published in 2004 continued to 
recommend life-long -blocker therapy to all AMI patients so long as no 
contraindications appeared.232 ESC guidelines for NSTE-ACS published in 
2007, however, suggested life-long -blocker therapy to only ACS patients 
with decreased LV function, whether symptomatic or not.372 For patients with 
preserved LV function, the guidelines did not provide any recommendations, 
although they stated that long-term -blocker therapy may lead to a significant 
reduction in mortality. Moreover, US guidelines from 2004 recommended -
blockers for all STEMI patients excluding low-risk patients (i.e., normal LV 
function, successful reperfusion and no significant ventricular arrhythmias) 
for whom prescribing β-blockers was still considered reasonable.373 Therefore, 
during recruitment for our study, the recommendations for -blocker use were 
already under review. Yet, the rate of -blocker prescriptions upon discharge 
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remained quite high in our study. Already in the first year following ACS, we 
observed a decrease in adherence rates to all secondary prevention 
medications and the rates continued to plummet until the end of follow-up. 
These trends mirror previous studies.15,228,254-256  
In addition, poor adherence to -blockers asssociated with an increased 
risk for both all-cause and coronary mortality across the entire ACS cohort. 
Although we observed a more prominent effect on better survival amongst 
high-risk patients, good adherence to -blocker therapy appears beneficial to 
low-risk ACS patients as well. Although the effect on coronary mortality was 
not statistically significant, a decreased risk for both all-cause mortality and 
rehospitalisations due to HF associated with good adherence to -blockers 
amongst low-risk patients. Previous studies were more in line with our 
findings for high-risk patients, although a few recent studies support the 
finding that low-risk patients irrespective of preseved LVEF also benefit from 
the continous use of -blockers.25,28,29,252,374  
The follow-up period in our study represents one of the lengthiest 
published to date in the adherence-mortality field, specifically regarding 
prospective studies. During follow-up, we observed a clear association 
between nonadherence to -blockers and an increased risk of negative 
outcomes even one year following the ACS event in our landmark survival 
analyses. Prior studies, however, suggest that the prognosis especially 
amongst low-risk patients, although even amongst ACS patients in general, did 
not improve with -blocker therapy one year after an MI. For instance, in a 
multicentre study by Puymirat el al., the discontinuation of -blockers after 
the first year did not increase long-term mortality amongst non-HF ACS 
patients.30 Furthermore, Dondo et al. concluded that the mortality of non-HF 
MI patients does not decrease with -blocker therapy even during the first year 
following an MI.26 Two recent Korean observational studies published in 2020 
reported contradictory conclusions from each other. Specifically, one 
proposed that only patients with lowered LVEF benefit from -blockers, whilst 
the other found that -blocker therapy benefits all ACS patients in a follow-up 
of at least up two years.375,376 Obviously, unwavering consensus remains 
beyond reach. However, our results indicate that continous -blocker therapy 
benefits all post-ACS patients, not only during the first year. Some recent 
observational studies, on the other hand, also support this.31,32,253  
After adjusting for multiple confounders, including the most prominent 
indicator of a risk profile, HF, examined as time-dependent variables and with 
accurate causes of death distinguishing all-cause and coronary mortalities 
separately, our study using an extensive follow-up carries multiple strengths 
supporting the results. Moreover, the utilisation of medications and adherence 
to -blockers, contrary to most studies, were analysed in a dynamic time-
dependent manner, allowing us to better mimic real-life situations.24 Both of 
our sensitivity analyses also indicated that even stricter adherence to -
blockers seems beneficial.  
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As described below, however, our study also carries several limitations. For 
instance, from this observational study we can only find associations between 
variables, not establish causal relationships between them. Considering the 
low-risk patient subgroup, the healthy adherer phenomenon may explain why 
no effect on coronary mortality contrary to all-cause mortality was observed 
with -blocker therapy. For instance, amongst nonadherent low-risk patients, 
other CV or lifestyle-dependent causes of death might be overexpressed. 
However, we did not examine this, and it, thus, remains mere speculation. 
Moreover, the worse prognosis amongst nonadherent ACS patients could, 
theoretically, be partly explained by -blocker withdrawal syndrome as 
opposed to merely the beneficial effects of -blocker use per se. It is more likely 
that patients discontinuing their -blocker therapy did so suddenly rather than 
through a stepwise decrease in their daily dosage. Therefore, it is possible that 
a nonadherent patient suffered from withdrawal symptoms and succumbed to 
a recurrent ACS, a ventricular arrhythmia or even an SCD due to the abrupt 
discontinuation of a -blocker. Yet, again, this remains unclear and is entirely 
speculative. Despite much study, particularly prior to the reperfusion era, the 
position and role of long-term -blocker therapy following ACS remains 
inconclusive. Further studies are needed to confirm which ACS patients 
benefit from continuous long-term β-blocker therapy and which do not. 
 
6.3 RBC TRANSFUSION 
Previous studies associated RBC transfusion with an increased mortality up to 
one year following an ACS event.334,377,378 Prior to our study, however, results 
from lengthier follow-up periods remained scarce.379 In our study, the need for 
RBC transfusion strongly associated with an increased mortality through the 
longest follow-up reported, even beyond the first year following discharge. 
Previous research established that patients treated with RBC transfusion are 
on average sicker, older and more fragile than patients not needing a 
transfusion. Our study mirrored those results. As in previous studies, RBC-
transfused patients were more often anaemic already at baseline, had more 
comorbidities such as diabetes and hypertension, experienced more severe 
CAD and presented with a weaker renal function than nontransfused 
patients.335,341,380 However, a recent meta-analysis of STEMI patients 
indicated that the association with increased mortality could not only be 
explained by transfused patients’ comorbidities.344 Although no direct causal 
relationship between RBC transfusion and mortality can be established from 
our observational study, in order to thoroughly adjust for these confounders 
and more firmly explain our results, we matched RBC- transfused to 
nontransfused patients using a propensity score. Ultimately, using the IPTW 
Cox regression model, we verified the strength of our results.  
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Yet, the bias from any unmeasured confounding can affect these findings. 
Furthermore, the main issue in studying the impact of RBC transfusion on 
prognosis remains whether the cause for any adverse effects is indeed the RBC 
transfusion itself or the indication for its necessity—that is, the anaemia or 
bleeding. In our study, we attempted to address this issue in two separate 
subanalyses. First, we assessed the effect of an RBC transfusion effect on 
survival in both anaemic and nonanaemic patients, finding that transfusion 
associated with an increased risk of mortality in both of groups. Second, 
amongst RBC-transfused patients, we detected no difference in mortality rates 
when patients with nadir–Hb >80 g/l were compared to those <80 g/l. These 
results suggest that RBC transfusion would independently affect survival 
irrespective of either anaemia or nadir–Hb. Previous studies were unable to 
conclude whether to employ a liberal or restrictive transfusion strategy on ACS 
patients, although suggestions for more beneficial outcomes relying on a 
restrictive strategy have been reported.303,332-336,345 Furthermore, a recent 
meta-analyses of critically ill ICU patients associated a restrictive strategy 
(transfusion threshold of Hb <70 g/l) with a diminished risk of MI.381 Our 
results lean towards the use of a restrictive strategy, although our findings 
provide no definitive conclusions.  
The underlying mechanisms for the possible causality of RBC transfusion 
and increased mortality remain unclear, although we may speculate. For 
instance, storage and packing markedly influence the physical and functional 
capabilities of RBCs, which may have a detrimental impact on their ability to 
produce the desired effect of increasing oxygenation.382 It seems that stored 
RBCs may also attenuate the effect of nitric oxide produced by the vascular 
endothelium. This reportedly results in a diminished ability to regulate 
regional blood flow in zones of ischemia and hypoxia, which naturally plays a 
crucial role in ACS patients.383 However, a recent Cochrane review of RCTs 
concluded that the length of time RBCs are stored does not impact 
mortality.384 RBC transfusions may also produce prothrombotic, 
proinflammatory and immunosuppressive effects. For instance, cytokines 
such as interleukin (IL)-1, IL-8 and tumour necrosis factor reportedly increase 
following the transfusion of stored RBCs.385,386 These can cause several 
immunomodulatory effects possibly inducing inflammation in coronary 
plaques and, thus, worsening coronary disease outcomes. Another previously 
quite scantily investigated explanation of the association between mortality 
and transfusion may lie in malignant disease.387,388 Thus, as a secondary 
analysis, we identified an association in the increased risk of cancer mortality 
in patients treated with RBC transfusion in our cohort. However, we found no 
effect on new cancer incidence. Perhaps, RBC transfusion-induced 
immunomodulatory effects, better known as transfusion-related immune 
modulation (TRIM), cause a latent or undiagnosed malignancy to progress, as 
suggested by some studies on cancer surgery.389 However, a more plausible 
explanation for this association suggest that, when treated with potent 
antithrombotic and anticoagulant agents, a patient with a previously 
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unmanifested tumour such as in the gastrointestinal tract begins to bleed, 
leading to RBC transfusion and ultimately to a cancer diagnosis. In general, 
however, we feel that this association should be further examined.  
Based on both our own and others’ studies, we cannot yet conclude that 
RBC transfusion causes a poorer prognosis. Yet, whilst evidence mounts, we 
feel that every possible action should be taken to minimise the need for an RBC 
transfusion. This could be achieved, for instance, by assessing patient’s 
bleeding risk followed by reducing the dosage of antithrombotic drugs, as well 
as by favouring radial instead of femoral access in CAG.298,349-351,390 However, 
further randomised trials to both clarify the relationship as well as to identify 
the safest strategies to treat bleeding and anaemic ACS patients with RBC 
transfusions are warranted.342 
 
6.4 NSAIDS 
Almost 50% of ACS patients in our cohort filled at least one prescprition for 
NSAIDs during the follow-up period. Considering that most NSAIDs for short-
term use are purchased over-the-counter (OTC) in addition to these filled 
prescriptions, we believe this figure is alarmingly high amongst coronary 
patients, although in agreement with previous studies.45,46,48,391,392 Whilst we 
observed a slight declining trend during follow-up, the proportion of patients 
filling at least one NSAID prescription each year remained quite steady at 
around 15% to 20%. Furthermore, the rate of patients filling three or more 
prescriptions annually did not significantly decrease with time. As previously 
stated, studies conducted upon the emergence of coxibs raised a concern 
regarding the unwanted cardiac effects related to the use of COX-2 inhibitors 
and subsequently to all NSAIDs. This led to withdrawing rofecoxib from the 
market in 2004 in the USA and, further, in 2007 to contraindications for all 
NSAIDs to patients with ischemic heart disease.42,43 The selection of our 
cohort between 2006 and 2008 coincided with these events. The somewhat 
downward trend in NSAID consumption observed in our cohort might reflect 
the emergence of evidence against their use. Yet, measured as DDDs/1000 
inhabitants/day, the OTC utilisation of the most-used NSAID—ibuprofen—in 
Finland was 23.37 in 2008, based on Finnish medicine statistics.393 
Accordingly, in 2018, that figure was 22.42, reflecting only a miniscule decline, 
at least at the population level.394 Moreover, the overall sales figures for 
ibuprofen to hospitals and pharmacies was 47.46 DDDs/1000 inhabitants/day 
in 2008, increasing to 49.73 in 2018. In contrast to OTC use, an increase in the 
trend for overall utilisation of ibuprofen occurred in the last decade. However, 
whilst rather conclusive evidence has increasingly mounted since then, such 
that guidelines already recommend avoiding all NSAIDs, we feel that the 




As anticipated from previous findings, we observed an increased risk for a 
composite endpoint of recurrent MI or death amongst current NSAID users in 
our multivariable analyses.36,265,266,285,286,395-397 However, we did not observe 
this effect in the absolute figures nor in our univariable analyses. Results from 
sensitivity analyses were similar. In our multivariable models, we adjusted for 
multiple confounding factors, including concurrent secondary prevention 
medications. Our study also benefited from the inclusion of only ACS patients 
diagnosed with CAG during an exceptionally lengthy follow-up period. 
However, our findings on the effect of current NSAID use on the composite 
outcome remains rather inconclusive given the discrepancy between our 
results from univariable and multivariable analyses. This is further addressed 
in the limitations section. 
That said, we further analysed the effect of NSAID use on the composite 
outcome in subgroups, finding a similar association between current NSAID 
use with a poorer outcome only amongst low-risk patients and in the 
multivariable analysis. The number of patients in the high-risk subgroup 
remained quite low, possibly partially explaining the nonsignificant result, 
although this finding might reflect nonadherence to guidelines amongst 
physicians. For instance, if a patient presents as otherwise healthy without 
major risk factors and suffered only one minor MI, NSAIDs might be 
misconsidered as a safe pain medication for them.44 In our cohort, we 
measured NSAID use as filled prescriptions, which was apparently more 
common amongst low-risk patients. Naturally, this is merely speculation and 
does not respresent a definitive conclusion to our study. However, to narrow 
the gap between evidence and practice, we feel that ACS patients should be 
reminded both during and after hospitalisation, if possible, to steer clear of 
NSAID use regardless of duration, the agent intended for use, dosage or the 
patient’s own residual risk.46,267,283,398,399 
 
6.5 LIMITATIONS OF THE STUDY 
Despite the many strengths of this study, including the extensive follow-up 
time amongst unselected, consecutive and angiographed ACS patients, this 
type of observational study carries specific limitations as well. Our cohort was 
collected from a university teaching hospital and consists of only Caucasian 
patients. This limits the generalisability of our findings. Yet, our cohort 
benefits from being prospectively gathered and unselected, with an 
exceptionally wide age range. In an observational study, one of the primary 
limitations stands as the bias in unmeasured confounders. Therefore, we can 
not establish causal relationships based on this type of study. However, trends 
and associations between interventions and outcomes after adjusting for 
multiple crucial variables were observed. In addition to these general 
limitations, in study II, one definite drawback consists of the lack of definitive 
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data on bleeding events and indications for RBC transfusion. In addition, we 
failed to incorporate data on laboratory samples regarding patients’ iron 
status, for example, ferritin and transferrin. Therefore, we were unable to 
investigate the effect of iron deficiency or the role of iron replenishment 
following RBC transfusion on transfused patients’ survival. 
Specific limitations also emerge when assessing the utilisation of and 
adherence to medications. First, data on medication usage are based on 
prescriptions filled and the time intervals between them, solely used as a 
logical proxy indicator of continuous medication use and not guaranteeing the 
actual consumption of a drug. The latest methods used in adherence studies, 
namely, ‘proportions of days covered’ or ‘medication possession ratio’ could 
not be employed due to the absence of information in SII’s Finnish 
Prescription Register on prescribed dosages. Second, in both studies I and III, 
the interval allowed between prescription refills was based on the assumption 
that a patient fills the prescription for the maximum reimbursement time they 
are entitled to, which stands at three months in Finland. In study I, the interval 
allowed was 180 days in the primary analyses, a quite loose definition for good 
adherence. In study III, adherence was measured differently, although an 
interval of 100 days was allowed in the case of a death. This measure should 
be more accurate if based on reimbursement time. However, in both cases due 
to definitions, a patient may have been falsely categorised as adherent whilst 
truly being nonadherent because of a possibly smaller supply of the refill. Yet, 
this should dilute rather than accentuate the positive effect of the adherence 
observed in our outcomes. This was also addressed in the sensitivity analyses. 
Third, we were unable to identify patients discontinuing medication based on 
a considered decision by a physician due to adverse or other effects in either 
of the adherence studies (studies I and III). Instead, these patients were 
categorised as either irregular users in study I or nonadherent patients in 
study III. Moreover, we were unable to further investigate the reasons for 
discontinuing statins or -blockers. Furthermore, in study III, we did not 
examine patients who were prescribed β-blocker therapy later during follow-
up (that is, no prescription upon discharge). In study I, on the other hand, we 
were unable to assess the impact of statin use on cholesterol levels, namely, 
LDL-C during follow-up. Statins in study I, all secondary prevention 
medications in studies III and IV and NSAIDs in study IV were assessed as 
pooled pharmacological groups based on ATC codes rather than as individual 
medical agents, resulting in certain limitations to the interpretation of our 
findings. This specifically applies to COX-1 and COX-2 inhibitors in study IV. 
In studies I and III, given that we assessed medications as pooled 
pharmacological groups, we did not identify patients who switched from one 
specific medical agent to another within the same medical group. Finally, as 
previously described, the healthy adherer bias always persists in adherence 
studies. In other words, patients who adhere to a certain medical therapy also 
lead to an otherwise healthier life, using other drugs more responsibly and 
generally taking better care of their well-being. 
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Additionally, we were unable to examine the OTC purchase of aspirin in 
study III and NSAIDs in study IV. Nonetheless, we argue that by assessing 
NSAID use with information on filled prescriptions rather than OTC purchases 
(which is not possible through Finnish registries) we could more accurately 
depict the continuous use of these drugs and determine the user status 
immediately prior to the outcome event. However, given the lack of 
information on the prescribed dosage, we estimated the days’ supply using the 
DDD values, which in turn created some uncertainties in our definition of a 
current NSAID user. Moreover, we did not know for which ailment patients 
used NSAIDs. Furthermore, we assessed the concomitant use of secondary 
prevention medications only based on the last refill using a similar DDD 
manner. This represents a suboptimal method, although it is better than 
nothing when attempting to adjust for any confounding factors. As stated 
previously, the discrepancy in the results from study IV in the univariable and 
multivariable analyses limits our certainty related to the findings on the effect 
of current NSAID use on recurrent MI or death. This discrepancy may be 
explained by a bias from unmeasured confounders, possibly causing a hidden 
multicollinearity in the regression analysis. However, we detected no 
multicollinearity between the variables included in our final models using the 
VIF values. In any case, our primary goal in study IV was to investigate the 
behaviour of NSAID utilisation in the years following an ACS event, which we 
achieved. 
In study III we were unable to investigate the effect of -blocker withdrawal 
syndrome on nonadherent patient survival. Moreover, we could not identify 
the proportion of SCD in the long-term mortality of ACS patients. Although we 
assessed HF as a time-dependent variable in study III, we could not adjust for 
the LVEF values in the multivariable analyses in any of the studies, since so 
many patients had missing values given that echocardiography was not 
routinely performed on every patient. 
Our subgroup results in studies III and IV are limited only to the subsets of 
patients with the conditions included in the risk profile definition. High-risk 
patients were defined as having one or more of the following: heart failure at 
baseline, triple vessel disease in CAG or a previous MI. Patients without any of 
these were definied as low risk.  
6.6 FUTURE PERSPECTIVES 
To summarise, our results indicate that ACS patients benefit from long-term 
statin and -blocker therapy, provided that they adhere to their continuous 
use without gaps in refilling prescriptions. It seems that years after an MI, 
patients should continue to avoid even short-term NSAID use. Our results also 
suggest that physicians should attempt to treat such patients using RBC 
transfusion only if necessary, to further improve the long-term prognosis of 
ACS patients. Given the nature of our observational study, however, these 
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trends and associations do not lead to definitive conclusions from this study. 
However, these findings provide a solid foundation for future studies.  
For all other subgroup of patients beyond ACS patients, guidelines for the 
safe use of RBC transfusions have been defined, and primarily indicate a 
restrictive transfusion strategy. Strong evidence supports RBC transfusion for 
ACS patients with Hb <80 g/l, whilst this is not indicated for patients with Hb 
>100 g/l.342,343 However, that inconclusive area causes confusion amongst 
physicians. Therefore, to clarify this issue, we argue that ACS patients with Hb 
between 80 g/l and 100 g/l should be randomised to either receive RBC 
transfusion or not. This could minimise the bias in the treatment indications, 
including for anaemia or bleeding. Furthermore, both guidelines and 
physicians have traditionally quite generally used an Hb-level cut-off as the 
indication for an RBC transfusion. However, most probably patient- specific 
individual characteristics such as age, comorbidities, sex, baseline Hb levels 
and chronic anaemia amongst others impact patients’ tolerance to a decline in 
Hb levels. Therefore, question is, whether we should measure instead the delta 
for the decline in Hb from baseline to nadir and make individual decisions to 
transfuse based on, for example, a validated risk score or is it safer to use 
familiar Hb trigger levels for all patients.400 Additionally, the association 
between RBC transfusion and cancer mortality should be further investigated. 
Furthermore, the effect of iron deficiency on prognosis amongst patients 
needing an RBC transfusion as well as the role of iron replenishment following 
a transfusion should be addresed in more depth in future. 
When it comes to adherence to secondary prevention medications, further 
knowledge on the multifactorial phenomena behind nonadherence should be 
examined. More individually targeted interventions should be investigated, 
preferably through RCTs, to improve adherence. Considering long-term -
blocker therapy in ACS patients’ secondary prevention an RCT amongst 
prespecified low-risk patients with preserved LV function should be conducted 
along with the utilisation of medications further adjusted with as precise of an 
adherence measure as possible. The -blocker withdrawal syndrome should 
also be taken into consideration as a possible phenomenon explaining the 
poorer prognosis of nonpersistent patients. Interestingly, the BETAMI trial 
has already begun recruiting patients and the trial protocol appears quite 
promising.401 This randomised multicentre study amongst 10 000 MI patients 
treated with PCI or thrombolysis with LVEF ≥40% or no clinical signs of heart 
failure should examine the superiority of -blocker therapy compared with no 
-blocker therapy in relation to all-cause mortality or recurrent MI over a 





We can draw the following conclusions based on these studies: 
 
1) The adherence rate to statins following ACS remains insufficient. In 
addition, a stepwise decrease in adherence to statins correlates with a 
corresponding increase in mortality. Patients initiating statin therapy 
soon after discharge appear to have better odds of remaining regular 
users and achieving a better prognosis as well.  
 
2) The association between increased long-term mortality and the need 
for RBC transfusion during acute treatment for an ACS event amongst 
non-CABG patients is evident. This association remains strong even 
after the first year of follow-up. 
 
3) The adherence rate to secondary preventive medications decreases 
drastically every year following an ACS event. Poor adherence to -
blockers amongst ACS patients associates with an increased risk of 
long-term mortality long after the event, even beyond the first year. The 
prognostic effect is more evident amongst high-risk patients, although 
continous -blocker therapy appears to decrease the risk of both all-
cause mortality and rehospitalisations for HF amongst low-risk ACS 
patients as well. 
 
4) Despite wide evidence on the risks to cardiac patients, NSAIDs are still 
prescribed to and used by an alarmingly high number of patients 
following an ACS event. The utilisation rate does not significantly 
decrease even several years after an ACS. The use of NSAIDs seems to 
associate with an increased risk of recurrent myocardial infarction and 
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